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ABSTRACT
Veratrum californicum, commonly referred to as corn lily or Californian false
hellebore, grows in high mountain meadows and produces bioactive steroidal alkaloids,
including cyclopamine. Cyclopamine is a potent inhibitor of the Hedgehog (Hh) signaling
pathway. Our lab has optimized methods to extract cyclopamine and related steroidal
alkaloids from V. californicum, and implemented in-house Hh signaling bioactivity
evaluation of these steroidal alkaloids using a Shh-Light II cell assay. A survey of
extraction methods and solvents resulted in the identification of conditions most
favorable for alkaloid extraction yield and antagonist activity in the Shh-Light II cell
assay. The highest amount of bioactive cyclopamine was obtained by soaking V.
californicum biomass in ethanol for 24 hr. with vigorous stirring. The extraction protocol
was effective for isolating additional alkaloids beyond cyclopamine, some of which have
been reported in the literature prior and some that have not. In all cases, bioactivity
screening was performed and new insights provided. Expansion of the extraction protocol
for the investigation of detailed differences in alkaloid composition of V. californicum
based on plant part, harvest location, and growth stage, provides a detailed assessment of
alkaloids that have been characterized previously (cyclopamine, veratramine, muldamine
and isorubijervine), and identifies at least six alkaloids that have not been previously
characterized.
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CHAPTER ONE: INTRODUCTION
1.1

The Hedgehog Signaling Pathway

Christiane Nusslein-Volhard and Eric Wieschaus first identified the Hedgehog
(Hh) signaling pathway during an investigation to survey genes that disrupt the larval
body plan in Drosophila. The name hedgehog was ascribed based on the appearance of
embryos with Hh mutations displaying disorganized, pointy, hair-like bristles similar to
hedgehog spines [1]. Later, the Drosophila Hh gene was discovered to code for a secreted
protein that directs pattern formation of adjacent cells [2-4]. The Hh signaling pathway is
critical in embryonic development, and is essential for orchestrating cell specification and
cell division required to form a functional organism [5,6]. Hh signaling is evolutionarily
conserved, and in mammals is vital for the formation of various tissues including the
neural tube, axial bone, hair, and teeth [7-9]. Hh signaling is inhibited in most adult
tissues, but continues in discrete populations of cells within many adult mammalian
tissues, presumably to control proliferation, specification, and cellular plasticity [10].
Continued Hh signaling activity in adults has been demonstrated in various organs,
including the brain, skin, and prostate [11-13]. Additionally, Hh signaling plays a role in
the proliferation and differentiation of germline stem cells in the gonads [14].
In mammals, the Hh signaling pathway consists of the secreted ligands Sonic
hedgehog (Shh), Desert hedgehog (Dhh) and Indian hedgehog (Ihh); the 12-pass
transmembrane protein receptor Patched (Ptch), the 7-pass transmembrane signal
transducer Smoothened (Smo), and the Gli transcription factors (Gli1, Gli2, Gli3) [15].
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Although the Hh ligand proteins all act as morphogens and have similar physiological
effects, each Hh ligand performs specialized functions due to the spatial and temporal
differences in their expression [16]. Shh is mostly expressed in the central nervous
system, lungs, teeth, gut, and hair follicles [17-21]. Ihh is a key regulator of endochondral
ossification and is expressed and secreted by prehypertrophic and early hypertrophic
chondrocytes during bone formation [22]. Dhh is expressed mostly in the Sertoli cells in
the gonads to aid in the proliferation and differentiation of germline stem cells [23]. The
Hh ligand proteins are synthesized as precursors of about 45 kDa, that undergo extensive
post-translational modifications, including self-cleavage in the endoplasmic reticulum,
conjugation of cholesterol to the C-terminus, and N-terminal palmitoylation, after which
they are released by the secreting cell and operate in paracrine or autocrine manner
[10,24]. Both the palmitoylation and cholesterol modification limit the free mobility of
the protein and result in association of Hh with sterol-rich microdomains in the
membrane [25,26]. Once at the outer surface of the plasma membrane, dually lipidmodified Hh ligand is associated with the lipid bilayer as a monomer until it is released
by one of four mechanisms: 1) The cholesterol-modified Hh monomer is released by the
cooperative action of the transmembrane protein Dispatched and the secreted SCUBE2
protein 2) monomeric Hh can also self-associate to form large soluble multimers that are
released from the membrane, 3) Hh oligomers can interact with the heparan sulphate
chains of glypicans, which enables them to recruit lipophorin apolipoproteins and
assemble into lipoprotein particles, or 4) Hh may be released at the surface of exovesicles
[27].
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In the absence of Hh ligands, Ptch prevents the translocation of Smo to the
primary cilia, thereby inhibiting the nuclear localization of Gli and suppressing
transcriptional activity. The exact mechanism of Ptch repression of Smo activity remains

Figure 1.1
Reception of Hedgehog and initiation of signal transduction. In
the “off” state, Ptch is enriched in the primary cilium where it inhibits Smo. In the
absence of Hh, the GLI proteins are phosphorylated by PKA, leading to their
proteolytic cleavage to generate the repressor forms. In the presence of Hh, Ptch
exits the cilium. Smo is phosphorylated and transported to the cilium, where the
activated Smo is anchored near the base of the cilium. The Sufu/Gli complex
accumulates at the tip of the cilium, where the complex dissociates. Upon exiting
the cilia, activated Gli proteins enter the nucleus to promote the transcription Hh
target genes.
unclear. Upon binding of Hh ligands to Ptch, Smo suppression is abolished and
downstream pathway activity proceeds, resulting in nuclear translocation and activation
of Gli. More specifically, when a Hh ligand binds to Ptch, the inhibition of Smo is
relieved, which disrupts the stability of the suppressor of fused (SuFu), kinesin family
member 7 (Kif7), and Gli complex, resulting in the release and nuclear localization of the
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Gli transcription factors [14]. In this process downstream of Smo inhibition alleviation,
the Gli transcription factors mediate the Hh signal transduction. This canonical activation
of Gli is depicted in Figure 1.1. The Gli transcription factors are bifunctional, and can
activate or inhibit transcription [27]. In the absence of Hh ligand, Gli2 and Gli3 are
phosphorylated by protein kinase A (PKA), glycogen synthase kinase 3 (GSK3), and
casein kinase 1 (CK1), and undergo limited proteasomal degradation in which their Cterminal activator domain is cleaved by beta-transducin repeat containing protein (βTRCP), which leads to the conversion into transcriptional repressors, entering the nucleus
and repressing Hh target genes. In the canonical Hh signaling pathway, Gli
transcriptional activators are formed only in response to Hh stimulation. Therefore, Hh
signaling functions through modulating the balance between Gli repressors and
activators. The cellular response of this repressor/activator ratio is diverse and context
dependent, with different tissues displaying differential expression patterns of target
genes in response to Hh ligands [28]. Additionally, some Hh signaling target genes
require positive input from Gli activators to initiate transcription, while others are
activated simply by removing the Gli repressor protein from the enhancer. Gli activators
bind to GACCACCCA motif to regulate transcription of various genes, including GLI1,
PTCH1, PTCH2, MYCN, HHIP1, CCND1, CCND2, BCL2, CFLAR, FOXF1, FOXL1,
PRDM1, JAG2, GREM1, and FST [29]. Hh signals are fine-tuned based on positive
feedback loop via GLI1 and negative feedback loop via PTCH1, PTCH2, and HHIP1.
Excessive positive feedback or collapsed negative feedback of Hh signaling due to
epigenetic or genetic alterations leads to carcinogenesis. Hh signals induce cellular
proliferation through upregulation of N-Myc, Cyclin D/E, and FOXM1. Hedgehog
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signals directly upregulate JAG2, indirectly upregulate mesenchymal BMP4 via FOXF1
or FOXL1, and also upregulate WNT2B and WNT5A. Hedgehog signals induce stem cell
markers BMI1, LGR5, CD44, and CD133, based on cross-talk with WNT and/or other
signals. Hh signals upregulate BCL2 and CFLAR to promote cellular survival, SNAI1
(Snail), SNAI2 (Slug), ZEB1, ZEB2, TWIST2, and FOXC2 to promote epithelial-tomesenchymal transition, and PTHLH (PTHrP) to promote osteolytic bone metastasis.

1.2

Teratogenic Alkaloids in Veratrum californicum and Elucidation of Their
Molecular Mechanism
During the 1940’s and 50’s, sheep herders in southwestern and south-central

Idaho observed that ewes that grazed in alpine ranges during summer months gave birth
to lambs with a variety of craniofacial deformities. These deformities included cyclopia, a
domed cranium, cleft palate, shortening of the upper jaw, malformation of the nose into a
proboscis positioned above the eye, hydrocephalus, and holoprosencephaly, or the failure
of the forebrain to sufficiently divide into the double lobes of the cerebral hemispheres,
resulting is a single-lobed brain structure [30]. In 1954, sheep herders in Idaho contacted
scientists at the Poisonous Plant Research Laboratory in Logan, UT, to request assistance
in identifying the cause of the malformed lambs [30-32]. Controlled breeding
experiments eliminated the possibility that the congenital anomaly was caused by genetic
factors and potential environmental elements or the presence of poisonous plants were
assumed to underlie the developmental anomalies. Field studies determined that
deformities occurred in lambs from ewes that grazed in meadows above 6,000 feet in
elevation, where Veratrum californicum is commonly observed to grow [30]. Controlled
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feeding trials of V. californicum in sheep reproduced the deformities observed in the field
and definitively validated the teratogenic role of V. californicum [33]. Efforts led by
researchers Richard Keeler and Wayne Binns focused on Veratrum alkaloids as the
causative agent, and they began to methodically test crude alkaloid fractions obtained
from ethanol and benzene soaks of V. californicum for their teratogenic potential.
Hydrophilic cevanine alkaloids were ruled out as the causative agent, and eventually
Keeler and Binns narrowed their search to fractions containing an unidentified glycoside
and alkamine, which they referred to as alkaloid X and alkaloid V, respectively [34,35].
Chemical investigation revealed alkaloid V to be 11-deoxojervine, first isolated by
Masamune et al. from V. grandiflorum in 1965, while alkaloid X was determined to be its
C-3 glycoside (see Figure 1.2) [36]. Keeler gave these compounds the trivial names
cyclopamine and cycloposine because of their teratogenic manifestation [37,38].
Definitive feeding trials in both sheep and rabbits with purified alkaloids established that
cyclopamine and cycloposine are responsible for the cyclopean-malformations [39,40].
Later, malformations in the heads of chicken embryos following exposure to cyclopamine
and jervine demonstrated teratogenic activity in non-mammalian vertebrates [41].
To gain a mechanistic understanding of how the key chemical features that
governed molecular teratogenicity of these compounds interfere with proper embryonic
development, derivative compounds and structurally related alkaloids were investigated.
For these studies, hamster models were used to limit the amount of material needed.
Alkylation of the nitrogen with a bulky moiety, such as N-butyl in jervine significantly
reduced the teratogenicity, whereas methylation and formylation retained the
teratogenicity of the alkaloid,
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Figure 1.2
Molecular structures of A) cyclopamine (11-deoxojervine) and B)
jervine. Structures of teratogenic steroidal alkaloids with atomic numbering system
shown. For A), replacement of the hydroxyl group attached to C3 with glucosyl
corresponds to cycloposine.

indicating that the steric and electrostatic state of the nitrogen atom is critical for
functionality [42]. Additionally, acylation or oxidation of the hydroxyl group in jervine
did not diminish biological activity, nor did hydrogenation of the C12-C13 double bond.
Following these structure-activity studies, investigators hypothesized the mechanism of
action to be interference of steroid hormone signaling in the developing embryo. This
was a logical conclusion based on structural similarities between steroid hormones, and
the C-nor-D-homosteroids to which cyclopamine and jervine belong. C-nor-Dhomosteroids possess a steroid skeleton with an unusual 6-6-5-6 ring pattern, rather than
cyclopentanophenanthrene skeleton which contains a 6-6-6-5 ring system characteristic
of steroid hormones (see Figure 1.5). It would take several decades, and advances in
other research fields to finally elucidate the enigmatic mechanism of these teratogenic
compounds.
With the discovery of Hh in Drosophilia by Nüsslein-Volhard and Wieschaus,
and the subsequent identification of their vertebrate homologs, a key observation hinting
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at a potential molecular mechanism for the teratogenic effect of cyclopamine was made
by Chiang and Beachy while working with Shh knockout mice [43]. They were using this
mouse model to study the role of the Shh secreted morphogen in vertebrate development.
Shh-/- mice displayed severe holoprosencephaly, extensive craniofacial deformities,
including cyclopia and a proboscis consisting of fused nasal chambers at a location
overlying the cyclopic eye. Based on the similarities in the developmental malformations
produced by the Shh knockout in mice and those described decades prior from pregnant
ewe consumption of V. californicum, it was speculated that cyclopamine and other
alkaloids might act through inhibition of Hh signaling. Later, using chick neural plate
explants, it was demonstrated that treatment with jervine recapitulated the Shh knockout
mouse phenotype by inhibiting the response of target tissues to Shh protein [44]. This
finding was corroborated shortly thereafter in chick embryos treated with cyclopamine,
and it was determined that cyclopamine-induced teratogenesis is due to direct antagonism
of Shh signal transduction [45]. Ultimately, it was determined using photoaffinity and
fluorescent derivatives, that cyclopamine inhibits Hh signaling by binding to and
blocking Smo [46]. These data were later corroborated by crystallographic analyses of
the Smo/cyclopamine complex, in which cyclopamine was observed to bind to the
internal heptahelical fold of Smo, rather than the extracellular domain of the cytoplasmic
C-terminus [47]. The Smo/cyclopamine complex is shown in Figure 1.3. Smo is a G
protein-coupled receptor that contains an extracellular domain composed of a cysteinerich domain and a linker domain, a seven-transmembrane helical domain and an
intracellular carboxy-terminal domain. Cyclopamine binds near to the entrance into a
long and narrow cavity inside the receptor.
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Figure 1.3. Cyclopamine binding to Smoothened receptor. (A) Receptor model of
Smoothened shown as a tan cartoon with cyclopamine shown to bind as a space-filled
model. The extracellular, transmembrane and intracellular domains of Smo are indicated.
Horizontal lines indicate membrane boundaries. Cyclopamine binds near to the entrance
into a long and narrow cavity inside the receptor. (B) Top view Smo receptor with
cyclopamine bound to the cavity near the transmembrane domain.

Cyclopamine was the first small molecule known to specifically inhibit the Hh
pathway, and has been widely used to study Hh signaling. Cyclopamine has also played
an important role in the development of Smo antagonists as therapeutic agents, as Hh
pathway activation not only controls tissue patterning but also contributes to oncogenesis.

1.3

The Hedgehog Signaling Pathway and Cancer

Abnormal activation of Hh signaling has been implicated in many cancer types
including gastrointestinal, bladder and ovarian carcinomas, lung cancer, and
hematological malignancies [48-55]. Aberrant Hh signaling also plays an important role
in cancer proliferation and invasiveness. Several molecular mechanisms in the aberrant
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activation of Hh signaling in human cancers have been identified. These include 1)
ligand-independent activation due to loss-of-function mutations in Ptch1 or SUFU that
inactivate the suppression of Hh signaling, or gain-of-function mutations that enhance the
activity of Smo or Gli, 2) ligand-dependent activation through tumor expression of Hh
ligands acting in a autocrine or juxtacrine manner, and 3) paracrine ligand-dependent
activation where Hh ligands are secreted by tumor cells turning on Hh signaling in the
surrounding tissues [56].
Depending upon tissue type, abnormal Hh signaling contributes to the progression of
specific cancers differentially [57]. In the case of basal cell carcinoma and
medulloblastoma, mutations in the Hh pathway initiate tumorigenesis [58,59]. In some
cancers, including colon and pancreatic, Hh signaling does not initiate tumorigenesis but
contributes to the growth of the tumor [60,61]. Finally, for many cancers including
lymphoma, lung and prostate, Hh signaling has been implicated but the exact role of the
pathway on progression of these diseases remains enigmatic [57]. In gallbladder cancer, it
has been demonstrated that Hh signaling promotes invasiveness through degradation of
collagen IV via upregulation of MMP-2 and MMP-9 collagenases [62]. Degradation of
collagen IV in the basement membrane is required for invasion into adjacent blood or
lymphatic vessels. Inhibition of Smo in gallbladder cancer cells was shown to decrease
cell invasiveness and inhibit epithelial-mesenchymal transitions. Therefore, suppression
of Smo and Hh signaling was identified as a potential therapeutic strategy for this cancer
type. In these cells, Smo inhibition resulted in decreased expression of vimentin, an
intermediate filament protein expressed in mesenchymally derived cells and cells
undergoing epithelial mesenchymal transition [63]. The association between Hh signaling
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and epithelial mesenchymal transition through downregulation of E-cadherin, a calciumdependent cell to cell adhesion protein, has also been reported [64]. The correlation
between Hh signaling and MMP-9 was identified to increase invasiveness of pancreatic
ductal adenocarcinoma cells [65]. In the case of prostate cancer, prostate fibroblasts have
demonstrated Smo-mediated Hh signaling resulting in increased proliferation and
dedifferentiation in adjacent epithelium [66]. Mounting evidence demonstrates that
perlecan and syndecans modulate sonic hedgehog signaling during both development and
neoplasia, in particular in prostate cancer by directly binding sonic hedgehog and
promoting its interaction with Ptch [67,68]. Furthermore, the activity of heparanase was
shown to modulate hedgehog signaling through degradation of heparin sulfate
glycosaminoglycans in the pathogenesis of medulloblastoma [69].
The initial link between Hh signaling and cancer came with the discovery that a
mutation in Ptch was responsible for Gorlin syndrome. Gorlin syndrome, also referred to
as nevoid basal cell carcinoma syndrome or basal cell nevus syndrome, is a rare,
autosomal-dominant genetic disorder characterized by rampant cancerous and
noncancerous tumor formation in various tissues, including the skin, cerebellum and soft
tissue [70-72]. Following this discovery, several mouse models for Hh pathway
activation were developed and studies in these mice demonstrated that constitutive Hh
signaling activity is sufficient to form basal cell carcinoma and medulloblastoma [73,74].
Additionally, mutations in Hh pathway genes have been associated with sporadic BCC
[75,76]. Over 90% of sporadic BCCs have mutations in one allele of Ptch, presumably
arising from DNA damage sustained by UV radiation [77].
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While cyclopamine has served as a valuable tool in basic research and preclinical
models, its potential as a therapeutic agent is limited due to poor solubility, acid lability,
and the significant potential for off target effects [78]. For this reason, academic and
industrial scientists have sought new Smo inhibitors. Several Smo inhibitors with
improved stability and potency over cyclopamine have been created, including IPI-926, a
semi-synthetic derivative of cyclopamine, and KAAD-cyclopamine, a cyclopamine
analog [79,80]. To date, three Smo antagonists have been approved by the United States
Food and Drug Administration for clinical use: vismodegib (GDC-0449) developed by
Genentech and approved by the FDA in 2012, sonidegib (LDE225) developed by
Novartis and approved by the FDA in 2015, and glasdegib (PF-04449913) developed by
Pfizer and approved by the FDA in 2018 [81-83]. The molecular structures of the above
mentioned compounds are shown in Figure 1.4. Both vismodegib and sonidegib are
highly effective treatments for advanced basal cell carcinomas that are not amenable to
surgical removal, and vismodegib was also reported to induce rapid but transient
regression of metastatic medulloblastoma [84]. Glasdegib is approved for use in
combination with low-dose cytarabine for the treatment of newly-diagnosed acute
myeloid leukaemia in patients aged ≥75 years or those who have comorbidities that
preclude use of intensive induction chemotherapy. However, these successes have been
coupled with emerging challenges. As in the medulloblastoma case, chemoresistance
occurs with a frequency that correlates with tumor grade [85,86]. Smo mutations
contribute to many of these relapses; however, genomic alterations
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Figure 1.4. Molecular structures of synthetic and natural Smo anatagonists.
Vismodegib, sonidegib and glasdegib are FDA approved Smo inhibitors.

involving downstream signaling components such as SUFU and GLI2 have been
observed as well. In addition, systemic Smo blockade can cause on-target side effects,
including hair loss, taste sensation deficits, and muscle cramps, and vismodegib and
cyclopamine have been reported to activate noncanonical Smo functions [87,88].
Overcoming these limitations through next-generation Smo inhibitors, alternative
delivery methods, and/or new Hh pathway-targeting strategies will be necessary to
complete the clinical vision initiated by cyclopamine.
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1.4

Overview of the Genus Veratrum and Biological Activity of Veratrum
Alkaloids

Veratrum is a genus of perennial, flowering plants in the family Melanthiaceae
with widespread distribution across the Northern Hemisphere and are endemic to
temperate and subarctic portions of Europe, Asia and North America [89]. Eleven
Veratrum species grow in North America. Several species of the Veratrum genus, such as
V. album, V. californicum, V. viride and V. nigrum, are poisonous to humans and animals,
and the principal toxic components are steroid alkaloids. More than 100 different
alkaloids have been identified from Veratrum spp and have been categorized into
jervanine, vertranine, cevanine, verazine and solanidine types according to their carbon
framework (see Figure 1.5). Among the many different steroidal alkaloids, two broad
groups have been isolated from Veratrum spp: those featuring the typical
cyclopentanophenanthrene skeleton of cholesterol containing a 6-6-6-5 ring system
(sometimes referred to as the Solanum alkaloids) and those which have a C-nor-Dhomosteroidal skeleton featuring a 6-6-5-6 ring system. Alkaloids of this latter group are
commonly referred to as Veratrum alkaloids and were some of the first steroidal alkaloids
ever characterized. Within the Solanum alkaloids, there are two further classes, those of
the verazine type featuring a distinct imine containing ring and those of the solanidine
type in which the nitrogen containing ring has become fused to the rest of the cyclic
system. The Veratrum alkaloids can be further divided into distinct structural groups: the
veratranine, jervanine, and cevanine types. The veratranine group is defined by the
presence of an aromatic D-ring, whereas alkaloids of the jervanine type feature a
tetrahydrofuran E-ring linking the amine containing F-ring to the D-ring through a spiro-
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connection at C-17 (see Figure 1.2 for the carbon numbering scheme). Cevanine
alkaloids are distinct from the other two classes of Veratrum alkaloids in that they have a
six-membered E-ring. Additionally, cevanine alkaloids are highly hydroxylated in
Veratrum plants, with 7–9 atoms of oxygen, and feature α-ketol and hemiketal (an
alcohol and ether attached to the same carbon) linkages between C-4 and C-9 of the A
and B rings respectively. Figure 1.5 shows C-nor-D-homo and
cyclopentanophenanthrene skeletons, along with the steroidal alkaloid type and
representative structures.
The first Hh pathway inhibitor to be identified was the plant-derived steroidal
alkaloid, cyclopamine, which binds directly to the transmembrane helices of Smo and
blocks cellular responses to Hh signaling [43-46]. However, additional molecular targets
for cyclopamine have been identified. Cyclopamine exhibited growth inhibition of
various human breast cancer cells independently of Smo, suggesting inhibitory activity to
other molecular targets unrelated to the Hh signaling pathway [90]. In human
erthroleukemia cells, cyclopamine was found to inhibit cell proliferation and induced
apoptosis through COX-2 overexpression via PKC activation and NF-κB pathway
inhibition [91]. Moving away from cancer, cyclopamine has also been shown to be a
potent and selective inhibitor of human respiratory syncytial virus (hRSV) transcription
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Figure 1.5. Molecular skeletons of C-nor-D-homo and cyclopentanophenanthrene
steroidal alkaloids. Species of the genus Veratrum produce two broad classes of
steroidal alkaloids: the Solanum alkaloids, which feature the classic
cyclopentanophenanthrene ring structure and the Veratrum alkaloids, which feature a
rearranged C-nor-D-homosteroidal ring structure in the C-ring is five membered and the
D-ring is six membered. Representative structures of the five categories of steroidal
alkaloids: jervanine, vertranine, cevanine, verazine and solanidine, are shown.

in vitro and in vivo [92]. It specifically impairs the function of the hRSV RNA-dependent
RNA polymerase complex by reducing expression levels of the viral antitermination
factor M2-1. Cyclopamine has also been shown to induce apoptosis by inhibiting PCA3
in human prostate cancer cells [93]. Additionally, cyclopamine has been shown to
sensitize tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)
resistant gastric cancer cells to TRAIL by increased expression of death receptor 5 via
endoplasmic reticulum (ER) stress induced by reactive oxygen species, and increased
proteasome degradation of survivin, a negative regulator of apoptosis [94].
Veratramine occurs in various Veratrum species, including V. album, V.
grandiflorum, V. viride, and V. californicum [89]. Veratramine has been shown to be
effective in lowering blood pressure, antagonizing Na+ channel activity, and also
potentially serotonin (5-HT) agonist activity, acting on presynaptic 5-HT neurons [95-
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97]. The administration of vertatramine induces generalized tremors, myoclonus, hindlimb abduction, backward gait, and Straub tail, similar to the 5-HT syndrome in mice.
Veratramine has also been shown to be a potent modulator of the transcription factor
activator protein-1 (AP-1), which regulates a variety of protein-encoding genes, and
participants in many cellular functions, including proliferation, transformation, epithelial
to mesenchymal transition, and apoptosis [98]. Isorubijervine occurs in various Veratrum
species, including californicum, viride, album and taliense [89,99]. Isorubijervine has
been shown to exhibit strong cardiovascular toxicity in mice, and have been
demonstrated to block voltage-gated sodium channels NaV1.3-1.5, specifically expressed
in cardiac tissue [99]. Recently, seven new veratranine-type alkaloids were isolated from
V. taliense and evaluated for their analgesic activity using an acetic acid induced writhing
model in mice [100]. V. taliense has been used in traditional Chinese medicine for pain
and inflammation. Veratridine, a cevanine-type steroidal alkaloid isolated from the
rhizomes of V. album activates voltage-gated Na+ channel by blocking their inactivation,
thereby prolonging the opening of the channel and the action potential, and augmenting
the contractions to cardiac stimulation [101]. The alkaloid alters the gating and
permeability properties of Na+ current, and the main symptoms of veratridine toxicity
include severe nausea, bradycardia, hypotension, difficulty breathing, salivation, and
muscle weakness [102]. Additional notable examples of cevanine alkaloids include
zygadenine, germine, protoverine and veracevine, all of which lead to similar
physiological effects as veratridine when ingested, including hypotension, bradycardia
and apnea [89]. These symptoms are referred to as the Bezold–Jarisch reflex.
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The Veratrum alklaoids are diverse, as are their biological activities. I anticipate
that Veratrum alkaloids will continue to be investigated as chemical probes for
scrutinizing biological mechanisms, and serving as inspiration for drug development.
Steroidal alkaloids are inherently biologically relevant because their molecular scaffolds
have complex structures containing abundant chiral centers, making them valuable lead
compounds for drug discovery as their molecular targets and mechanisms of action
continue to be elucidated.
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CHAPTER TWO: CYCLOPAMINE BIOACTIVITY BY EXTRACTION METHOD
FROM VERATRUM CALIFORNICUM

Picture 1.

Graphical abstract for “Cyclopamine bioactivity by extraction
method from Veratrum californicum”
2.1

Foreword

The following chapter was published in the journal Bioorganic and Medicinal
Chemistry in 2016 [103]. The purpose of this manuscript was to correlate the extraction
efficiency of cyclopamine from Veratrum californicum by eight different methods to the
bioactivity of the cyclopamine to inhibit Hedgehog signaling, given that extraction
techniques may isomerize the alkaloid resulting in diminished bioactivity. Bioactivity
assessment was performed by Shh-Light II cells using the Dual-Glo® Luciferase Assay
System. These results correlated for the first time alkaloid recovery efficiency from
biomass to steroidal alkaloid inhibition of the Hh pathway. This investigation assessed
the limits associated with alkaloid recovery and identified an optimal method to obtain
the highest yield of active cyclopamine.
2.2

Abstract

Veratrum californicum, commonly referred to as corn lily or Californian false
hellebore, grows in high mountain meadows and produces the steroidal alkaloid
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cyclopamine, a potent inhibitor of the Hedgehog (Hh) signaling pathway. The Hh
pathway is a crucial regulator of many fundamental processes during vertebrate
embryonic development. However, constitutive activation of the Hh pathway contributes
to the progression of various cancers. In the present study, a direct correlation was made
between the extraction efficiency for cyclopamine from root and rhizome by eight
methods, and the associated biological activity in Shh-Light II cells using the Dual-Glo®
Luciferase Assay System. Alkaloid recovery ranged from 0.39-8.03 mg/g, with ethanol
soak determined to be the superior method to obtain biologically active cyclopamine.
Acidic ethanol and supercritical extractions yielded degraded or contaminated
cyclopamine with lower antagonistic activity towards Hh signaling.
2.3

Introduction

Veratrum californicum (V. californicum), a plant that is rich in steroidal alkaloids,
is native to moist, high elevation regions in the western United States [104,89]. Of these
alkaloids, cyclopamine has been studied for its effect as a teratogen through antagonism
of the Sonic Hedgehog (Shh) signaling pathway, which is principally active during fetal
development [40,44,45,105-107]. Inhibition of Shh signaling has gained recent interest
due to the discovery that aberrant pathway activation is significant in the progression of
over twenty cancers including prostate, gallbladder, pancreatic, and basal cell carcinoma
[54,62,64-66,89,108]. Active drug development in this field has either used the structure
of cyclopamine as a model from which to develop new cancer chemotherapeutics, as in
the case of vismodegib developed by Genentec, or has synthetically altered the natural
product, as was done by Infinity Pharmaceuticals to make IPI-926, a drug candidate that
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has undergone phase two clinical trials for treatment of recurrent head and neck cancers
[80,109,110].
Continued development of Shh inhibitors may increase demand for harvesting V.
californicum as a natural source of cyclopamine, primarily from roots and rhizomes.
Preliminary studies to extract cyclopamine from V. californicum were performed by
soaking the biomass in benzene for 36 hours [35]. The extraction efficiency of benzene
was improved by switching from soaking the biomass for long periods of time to
employing Soxhlet reflux [111]. Additional efforts to reduce extraction time and improve
product yield include microwave assisted extraction, or alternatively, deglycosylation of
cycloposine prior to collection of cyclopamine [112-114].
Chandler et al. took advantage of the high solubility of alkaloids in ethanol and the
improved extraction efficiency using Soxhlet to obtain nearly three-fold increase in the
amount of cyclopamine as compared to traditional benzene extraction [114]. While
higher yields were achieved by ethanol extraction, it was not determined if the collected
cyclopamine retained biological activity. Cyclopamine has been reported to degrade to
veratramine or inactive isomers under acidic, aqueous conditions [39,115]. Literature and
patent review provided no comprehensive investigation to correlate extraction efficiency
to the potency of Shh inhibition.
In the current study, the total yield and biological activity of cyclopamine recovered
from V. californicum root and rhizome using eight extraction techniques was correlated
directly to alkaloid activity. Extractions were performed by Soxhlet reflux with benzene,
Soxhlet reflux with ethanol in acidic, neutral, and alkaline conditions, ethanol soak,
benzene soak, supercritical fluid, and ethanolic microwave assisted extraction (MAE).
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Cyclopamine was isolated by high performance liquid chromatography (HPLC), and
biological activity was tested using Shh-Light II cells.
2.4

Materials and Methods

2.4.1 Extraction of Cyclopamine
Solvents and Reagents: Extraction solvents, 95% EtOH, benzene, HCl, and
NH4OH were purchased from Fisher Scientific (Pittsburgh, Pennsylvania). HPLC mobile
phase consisted of 18 MΩ H2O and HPLC grade trifluoroacetic acid (TFA), formic acid
and acetonitrile (>99% purity, Fisher Scientific). Alkaloid standards for cyclopamine and
veratramine were purchased from Logan Natural Products (Logan, Utah), and additional
cyclopamine was purchased from LC Laboratories (Woburn, Massachusetts) and Alfa
Aesar (Ward Hill, Massachusetts).
Obtaining and Preparing Biomass: A complete specimen of V. californicum was
harvested at an elevation of 2134 m (~7000 ft), from a northwest facing slope, growing in
a moist meadow near the Elk Meadows trail at Bogus Basin Mountain Resort, located in
the Boise National Forest, Idaho. The leaf and stalk of the plant were separated from the
rhizome and roots, and all plant parts were cut into smaller pieces to fit into quart size
Ziploc bags. The sealed bags were placed in a cooler on a bed of ice for transportation.
The biomass was collected at a late stage in the plant’s life cycle; the plant had noticeable
brown edges along its leaves and top indicating annual deterioration of above ground
material in preparation for winter. Within two hours and upon arrival in the lab, the roots
and rhizomes were chopped into 2 cm segments and dried for 14 hrs. using a LabConco
Freezone 4.5 freeze drying unit, followed by storage at -20 ºC. Prior to usage, the frozen
biomass was again lyophilized to ensure dryness, flash frozen in liquid nitrogen, and
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ground to a fine powder by mortar and pestle. The homogenized biomass from the same
plant was used to perform each of the following extraction methods in triplicate.
Soxhlet Reflux (Ethanol and Benzene): Approximately 2.0 g of pulverized
biomass was packed inside a 25 mL cellulose thimble, which was placed into a Soxhlet
column, and fitted with a 500 ml round bottom flask containing 150 ml of either ethanol
or benzene. The Soxhlet reflux was maintained for 6 hrs. After 6 hrs., the reflux solvent
turned a dark amber color, and assumed a syrup-like consistency upon solvent reduction
by rotary evaporation.
Soak Extraction (Ethanol and Benzene): Approximately 2.0 g of pulverized
biomass was added to a 250 ml round bottom flask followed by 150 mL of ethanol or
benzene. The resultant slurry was sonicated for 30 min. and then stirred for 24 hrs. on a
stir plate. The amber extract was vacuum filtered through 0.45 μm Whatman filter paper.
Supercritical Fluid Extraction: A tight coil of copper wire was placed inside a 15
mL Falcon tube with a handle to help lower the coil. The wire was lowered leaving a 1
mL gap between the coil and the bottom of the tube. Two grams of biomass were packed
firmly on top of the copper coil. Dry ice was ground into a powder and packed to the top
of the tube. The cap was firmly sealed and the entire tube was submerged in warm tap
water. The reaction was considered complete when solid and liquid CO2 were no longer
present and bubbles ceased to appear in the submersion tank. Dry ice was added an
additional three times to ensure complete extraction. The biomass and filtrate were rinsed
with ethanol to remove residue from the tube. Ethanol fractions were combined for later
chemical analysis.
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Microwave Extraction: Microwave assisted extraction method was performed on
2.0 g pulverized biomass using 50 mL of 67% ethanol and 33% water (v/v). Sodium
carbonate (15 g/L) was added to ensure alkaline conditions (pH 10). The microwave
assisted extraction was performed using a CEM MARS 5 system. The reaction vessel was
heated from room temperature to 120 °C over three minutes. The temperature was held at
120 °C for three minutes using a power of 100 W. A subsequent 20 min. cool-down
period resulted in a solution temperature of less than 55 °C. The solution was transferred
to a 250 mL round bottom flask and evaporated to a volume of approximately 10 mL
using a rotary evaporator (35-50 °C), followed by vacuum filtration to obtain the
concentrated extract.
Crude Product Preparation: The crude extract obtained from each method was
dissolved in 10 mL of ethanol, and the solution was warmed and sonicated to achieve
complete dissolution. Addition of NH4OH achieved alkaline solvent conditions of pH
>10. The aqueous solution was added directly to a supported liquid extraction (SLE)
column (Chem Elut, Agilent, Santa Clara, California) and allowed to adsorb for 10 min.,
followed by elution of alkaloids with chloroform (3×10 mL) using a vacuum manifold set
to a pressure of 2 mbar. The chloroform fractions were combined, filtered, and
evaporated to dryness. All samples were dissolved in 1 mL ethanol as a mixture of
alkaloids.
2.4.2. Purification, Quantification, and Qualitative Analysis of Cyclopamine from
Extracts
Cyclopamine Purification: HPLC was used to purify cyclopamine from the alkaloid
mixture using a Dionex UltiMate ® 3000 uHPLC system coupled to a diode array detector
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(DAD) and an automated fraction collector. A semi-preparative Agilent Zorbax SB-C18
column (9.4 × 250 mm, 5 µm) was used to achieve separation. The mobile phase was
0.1% TFA in water (Buffer A) and acetonitrile (Buffer B) with a flow rate of 3.0 ml/min.
The linear gradient method was used to separate alkaloids from the mixture starting at 5%
acetonitrile and ending at 90% acetonitrile over 25 min. Cyclopamine isolated by this
procedure was stored as a dried solid at -20 °C for use in bioactivity studies and mass
spectrometry analysis.
Cyclopamine Quantification: Aliquots of crude alkaloid extracts were used to
quantitate cyclopamine content using a charge aerosol detector (CAD), and MSQ Plus
mass spectrophotometer equipped with a Thermo Acclaim 120 C18 column (2.1 × 150
mm, 3 µm). Buffer and gradient conditions were the same as stated above, but the flow
rate was decreased to 0.3 ml/min. Cyclopamine standard was used to create a calibration
curve at concentrations of 0.5, 1.0, 2.5, 5.0 and 10.0 mM with detection recorded by a
Corona Veo RS CAD with the power function set to 1.70. The quantity of cyclopamine
was determined from the alkaloid mixtures obtained from each extraction method
performed in triplicate, and the extraction efficiency and the standard deviation was
calculated.
Qualitative Analysis of Cyclopamine: Cyclopamine isolated from each alkaloid
mixture was analyzed by mass spectrometry using an ultra-high resolution Quadrupole
Time of Flight (QTOF) instrument (Bruker maXis). The electrospray ionization (ESI)
source was operated under the following conditions: positive ion mode; nebulizer
pressure: 0.8 Bar; flow rate of drying gas (N2): 4 L/min; drying gas temperature: 200 °C;
voltage between HV capillary and HV end-plate offset: 3000 V to −500 V; mass range
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was set from 80 to 1000 m/z; and the quadrupole ion energy was 4.0 eV. Samples were
analyzed by direct infusion with a syringe pump at a flow rate of 240 μL/hr. Sodium
formate was used to calibrate the system in the mass range. Spectra were collected for
intact parent ions followed by isolation and fragmentation using collision induced decay
MS/MS over a range of collision energies (0-40 eV). Fragmentation patterns were
compared to cyclopamine and veratramine standards. Data were analyzed using the
Compass Data Analysis software package (Bruker Corporation, Billerica,
Massachusetts).
2.4.3. Biological Activity of Purified Extracts
Cell Culture: Shh-Light II cells (JHU-068) were maintained in Dulbecco's Modified
Eagle Medium (DMEM) (Gibco) supplemented with 0.4 mg/mL geneticin, 0.15 mg/mL
Zeocin™ (Invitrogen), and 10% bovine calf serum. The cells were grown at 37 °C in an
atmosphere of 5% CO2 in air and 100% relative humidity. This mouse embryonal NIH
3T3 cell line contains a stably transfected luciferase reporter with eight copies of the
consensus Gli binding site [116]. Cyclopamine samples were dissolved in ethanol and
added to DMEM media containing 0.5% bovine calf serum.
Reporter Assay: Shh-Light II cells were seeded in a 96-well plate and grown to
complete confluence in the media described above. When cells were confluent, the media
was replaced with DMEM supplemented with 0.5% bovine calf serum, and treated with
0.1 ng of N-terminal mouse recombinant Shh (R&D Systems, Minneapolis, Minnesota)
dissolved in DMEM, and select cyclopamine treatment. To determine the effect of
extraction technique on the biological activity of cyclopamine, the collected material
from each of the eight extraction methods and three commercial cyclopamine standards
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were used to create treatments that resulted in final concentrations of 5, 1, 0.5, 0.1, or 0
(positive control) µM cyclopamine. In each experiment, the controls and treatment wells
contained all vehicles, with a final ethanol concentration of 0.05%. Gli activity in the
Shh-Light II cell line was assayed 48 hrs. after treatment with Shh protein and selected
compounds using the Dual-Luciferase Reporter Assay System (Promega, Madison,
Wisconsin). The Gli-activity was measured by luminescence emitted from cells using a
BioTek Synergy H1m Microplate reader. Each experiment was performed thrice.
2.5

Results and Discussion

HPLC chromatograms for crude extracts representative of each of the eight extraction
methods are shown in Figure 2.1. When necessary, crude samples were spiked with
standard to definitively identify the peak corresponding to cyclopamine. Alkaloids
typically found in V. californicum are shown in Figure 2.2. Each extraction technique
yielded a unique array of compounds with differing concentrations of alkaloids in relation
to the amount of cyclopamine. The complex sample matrices influence the elution time of
cyclopamine as compared to the isolated standard, so peak verification was necessary for
correct identification.
Soxhlet reflux with ethanol was found to be optimal when the extraction time was
allowed to proceed for 6 hours (data not shown). This time was determined by testing the
extraction efficiency at six points: 1, 2, 4, 6, 8 and 24 hours. As extraction time was
allowed to increase there was a corresponding increase in extracted cyclopamine, which
achieved a maximum at 6 hrs. after which cyclopamine quantity was observed to
decrease. It was assumed that prolonged exposure to elevated temperatures degraded
cyclopamine, but the nature of the degradation was not investigated.
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Figure 2.1. Chromatograms for alkaloid mixtures collected over a 30 minute run
time. All chromatograms are shown over the same intensity range (y-axis), and the
isolated peak is indicated by asterisks. Extraction conditions are as follows: a) benzene
soak, b) ethanol soak, c) microwave assisted, d) supercritical CO2, e) acidic ethanol
Soxhlet, f) alkaline ethanol Soxhlet, g) neutral ethanol Soxhlet, and h) benzene Soxhlet.
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Figure 2.2. Molecular structures of steroidal alkaloids present in V. californicum.
Shown are cyclopamine, veratramine, isorubijervine and muldamine.

Cyclopamine from each extraction technique was quantified from crude samples
by HPLC-CAD, and a standard curve generated from commercially available
cyclopamine (R2= 0.9972). The concentration of cyclopamine in crude alkaloid extracts
was determined and the efficiency of the cyclopamine extraction was calculated as a
function of dry material from which it was extracted. The cyclopamine extraction results
are summarized in Table 1. Table 1 shows the mg of cyclopamine extracted per g of
initial biomass. Each extraction was repeated in triplicate, and the standard deviation of
the yield is shown. The percent recovery relative to ethanol soak extraction is shown for
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Table 1.
Comparison of extraction efficiency and corresponding bioactivity of
cyclopamine. Recovery is reported as mg of alkaloid per g of biomass used.
Extraction Method

Average
(mg/g)

Standard
Deviation (mg/g)

Ethanol Soak
8.03
0.13
Benzene Soak
0.39
0.18
Benzene Sox
0.95
0.32
Ethanol Sox
0.75
0.14
Ethanol Sox (acidic)
0.11
0.02
Ethanol Sox (basic)
0.73
0.11
Supercritical
0.66
0.10
Microwave
1.19
0.53
*
Statistically lower bioactivity than cyclopamine standard.

Relative %
Recovery
100.0
4.9
11.8
9.3
1.4
9.1
8.2
14.8

Relative GliReporter Activity at
0.1 μM
40.45 ± 8.49
42.68 ± 2.74
45.17 ± 7.63
57.10 ± 7.29
91.10 ± 5.98*
40.14 ± 8.61
90.40 ± 6.50*
65.16 ± 8.63

comparison between extraction methods, because recovery from ethanol soak was
superior to all other methods. The activity of cyclopamine isolated by each extraction
technique to inhibit Hh signaling at 0.1 μM is also shown, where comparable high
inhibition was observed for ethanol and benzene soak, and Soxhlet under conditions of
benzene solvent or alkaline ethanol, and poor bioactivity was measured for acidic ethanol
Soxhlet and supercritical fluid extraction methods. In Table 1, the acidic ethanol Soxhlet
and supercritical extracts are indicated in bold font and by an asterisks to show reduced
biological activity compared to the cyclopamine standard, which measured at 58.08 ±
7.51 percent reduction in Gli-reporter activity at 0.1 μM cyclopamine treatment.
The amount of recovered cyclopamine by ethanol soak was substantially greater than
that obtained by other techniques, yielding 8.03 mg/g, compared to 0.39 to 1.19 mg/g.
Based on literature precedent, it is likely that prolonged ethanol exposure results in
deglycosylation of cycloposine to cyclopamine, while simultaneously providing a mild
solvent condition that prevents cyclopamine degradation [112]. The acidic ethanol
Soxhlet extraction yielded virtually no detectable cyclopamine of the correct m/z. Despite
this, as indicated in Figure 2.1, the major peak in the acidic ethanol Soxhlet extraction
was collected and evaluated for inhibitory activity towards Hh signaling.
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All extraction methods yielded a white, amorphous powder upon isolation except the
acidic ethanol Soxhlet and supercritical extraction methods. These methods yielded
brown and tan powders, respectively. Cyclopamine has been reported to degrade to
veratramine or isomerize under acidic conditions, resulting in reduced bioactivity
[39,115]. Therefore, it was anticipated that extraction by Soxhlet reflux using acidic
ethanol as the solvent, would yield a product of diminished effectiveness to inhibit Hh
signaling. High resolution QTOF MS showed the product obtained under acidic
conditions was characterized by an m/z and fragmentation pattern consistent with
veratramine [114], with a [M+H]+ peak of 410.304, and major fragmentation peaks of
295.2, 114.1, 183.1, 211.1, 171.1, and 84.1 (Figure 2.3).

Figure 2.3. Direct comparison of MS and MS/MS of the acidic ethanol Soxhlet
isolated product and veratramine standard. a) High resolution MS analysis of acidic
ethanol Soxhlet extracted product, and b) MS/MS analysis of isolated ion of m/z of
410.0. c) High resolution MS analysis of veratramine standard, and d) MS/MS analysis of
isolated ion of m/z of 410.0.
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To confirm that each extraction method yielded biologically active cyclopamine
capable of Hh pathway inhibition, the isolated cyclopamine was tested alongside three
commercially available cyclopamine standards from different suppliers in a Hhresponsive fibroblast cell line Shh-Light II assay [116]. Extracted cyclopamine from all
methods was able to decrease Shh peptide-stimulated Gli reporter activity at a level
equivalent to the cyclopamine standards for each concentration tested, except for
supercritical CO2 and acidic ethanol Soxhlet (Figure 2.4).
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Figure 2.4. Effects of extract on Shh-stimulated Gli-responsive promoter in the
Shh-Light II cell line. Shh-Light II cells were treated with various compounds in the
presence of 2 μg/mL mouse recombinant Shh for 48 h. a), b), c), and d) correspond to 5,
1, 0.5, and 0.1 μM cyclopamine, respectively, for each extraction method. Experiments
were performed in triplicate with standard deviation indicated.

Included in Figure 2.4 is average of the triplicate trials of the three commercial
standards. With the exception of the supercritical CO2 and acidic ethanol Soxhlet
extraction methods, each technique and the standard control resulted in nearly complete
(>98%) inactivation of the Shh peptide-stimulated Hh pathway activity at both 5 µM and
1 µM, and an average of 13.5±5.3% and 49.4±9.8% of reported activity at 0.5 µM and
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0.1 µM, respectively. Based upon the similarities observed in the biological activity, all
extraction techniques except the supercritical fluid and acidic ethanol Soxhlet can be
presumed to have yielded cyclopamine with chemical and isomeric purity equivalent to
that of the three commercial cyclopamine standards tested. The purity of the standards
was confirmed to be >98% by integrating the peak area of the high resolution QTOF MS
(see Figure 2.7).
Inhibition of Hh signaling was observed in Shh-Light II cells treated with acidic
ethanol Soxhlet isolated product, although at considerably decreased potency compared
to other extraction techniques and cyclopamine standards. Gli-reporter activity was
measured at 8.8±1.3%, 30.0±6.0%, 65.9±3.8%, and 91.1±6.0% for 5, 1, 0.5, and 0.1 µM
samples, respectively. To further investigate the identity of this acid degraded product,
the inhibitory activity of veratramine standard on Hh signaling in Shh-Light II cells was
performed. Inhibition was observed in the cells treated with the standard, but it was
markedly less potent than the acid degraded product. The relative Gli-report activity
measured at 72.0% for the cells treated with 1 µM veratramine standard, compared to
30.0% activity for cells treated with 1 µM acid degraded product (see Figure 2.5).

Figure 2.5. Direct comparison of Shh-Light II cells treated with 1 µM
veratramine standard, compared to 1 µM acid degraded product from acidic
ethanol Soxhlet extraction.
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The result displayed in Figure 2.5 may be due to presence of additional alkaloids in
the acidic ethanol extract, such as peaks observed at m/z 540.534, 416.351 and 430.330
as shown in the MS (Figure 2.3a), and trace quantities of residual cyclopamine.
Veratramine has been reported to be ineffective in blocking hedgehog signaling in chick
embryos at 240 nM, but acid treated cyclopamine has been shown to inhibit Hh signaling
with a diminished potency in Shh-Light II cells at 1 µM [45]. These discrepancies could
be the result of the disparate techniques and concentrations used to evaluate disruption of
Hh signaling. Decreased bioactivity for cyclopamine extracted by supercritical fluid was
also observed. The high resolution QTOF MS of this sample showed a veratramine
contaminate, as evidenced by a [M+H]+ of 410.3. Veratramine in the supercritical extract
was observed in each of the triplicate trials, indicating the crude sample matrix from this
extraction technique made the separation and isolation of pure cyclopamine less efficient
on the semi-preparative C18 HPLC column. In the acidic ethanol Soxhlet extractions
spiked with cyclopamine standard, there are clearly distinct peaks observed for
veratramine and cyclopamine (Figure 2.6). This is not the case for the supercritical fluid
extraction, indicating that the unique constituents of the crude supercritical fluid extract
made collection of cyclopamine independent of veratramine more difficult. However, it is
not immediately clear why this phenomenon is observed. From integration of MS peaks,
the supercritical extract yielded cyclopamine that was 79.4% pure, with the remainder of
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the mixture being primarily veratramine (Figure 2.7).

Figure 2.6. Comparison of acidic ethanol Soxhlet extraction and supercritical
fluid extraction spiked with cyclopamine standard. Distinct peaks observed for
veratramine and cyclopamine are observed in the acidic ethanol extraction, but not the
supercritical fluid extraction.
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Figure 2.7. MS analysis of cyclopamine standards and collected from
supercritical fluid extraction. a) and c) show confirmation of cyclopamine purity from
commercial standards, and b) MS/MS fragmentation of cyclopamine collected by
collision induced decay (CID). CID was collected at 50eV. d) shows direct injection of
cyclopamine collected from supercrititcal extraction. The presence of veratramine
observed at m/z 410.3 indicates a mixture of alkaloids.
2.6

Conclusion

Most of the extraction techniques evaluated in this study yielded cyclopamine
with purity that is comparable to commercially available sources, as demonstrated in Hh
signaling inhibition assay. The ethanol soak method yielded substantially higher
quantities of cyclopamine compared to the other methods. Acidic ethanol Soxhlet
extraction caused cyclopamine to degrade. The degradation product is suspected to be
veratramine, although it demonstrated Hh inhibition at considerably increased potency
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compared to commercially available veratramine standard. Veratramine was also present
in the supercritical fluid extract because the separation method comprised of HPLC
mobile phase and semi-preparative C18 column were not well enough refined to
completely separate these closely related chemical species. The identity of the unique
assortment of alkaloids resulting from each extraction technique warranted further
investigation, as did the precise chemical nature of the acid degraded product.
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CHAPTER THREE: NATIVE V. CALIFORNICUM ALKALOID COMBINATIONS
INDUCE DIFFERENTIAL INHIBITION OF SONIC HEDGEHOG SIGNALING

Picture 2.

Graphical abstract for “Native V. californicum alkaloid combinations
induce differential inhibition of Sonic hedgehog signaling”
3.1

Foreword

The following chapter is based on a manuscript published in the journal
Molecules in 2018 [117]. The purpose of the manuscript was to present the most
comprehensive quantitative and qualitative analysis of ethanolic extracts of aerial plant
(stem and leaf) and compare the bioactivity using Shh-Light II cells to alkaloids in the
root/rhizome. The paper went on to describe the evaluation of known Veratrum
californicum steroidal alkaloids, at the ratio identified by plant part, as compared to plant
extract for inhibition of Hedgehog signaling inhibition. Finally, mass spectrometry
analysis provided evidence that as many as eleven novel alkaloids, present in raw plant
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extracts, may contribute to Hedgehog signal inhibition. The bioactivity was assessed by
Shh-Light II cells using the Dual-Glo® Luciferase Assay System. The current
investigation identified alkaloids suspected to be Hedgehog signaling inhibitors for
isolation and bioactivity assessment.
3.2

Abstract

Veratrum californicum is a rich source of steroidal alkaloids such as cyclopamine,
a known inhibitor of the Hedgehog (Hh) signaling pathway. Here we provide a detailed
analysis of the alkaloid composition of V. californicum by plant part through quantitative
analysis of cyclopamine, veratramine, muldamine and isorubijervine in the leaf, stem and
root/rhizome of the plant. To determine if additional alkaloids in the extracts contribute to
Hh signaling inhibition, we replicated the concentrations of these alkaloids observed in
extracts using commercially available standards and compared the inhibitory potential of
the extracts to alkaloid standard mixtures using Shh-Light II cells. Alkaloid combinations
enhanced Hh signaling pathway antagonism compared to cyclopamine alone, and
significant differences were observed in the Hh pathway inhibition between the stem and
root/rhizome extracts and their corresponding alkaloid standard mixtures, indicating that
additional alkaloids present in these extracts are capable of inhibiting Hh signaling.
3.3

Introduction

The Hedgehog (Hh) signaling pathway plays a vital role in embryonic
development [6,75]. In mammals, the Hh signaling pathway consists of the secreted
ligands Sonic hedgehog (Shh), Desert hedgehog (Dhh) and Indian hedgehog (Ihh); the
transmembrane receptor proteins Patched (Ptch1 and Ptch2), the transmembrane signal
transducer Smoothened (Smo), and the Gli transcription factors (Gli1, Gli2, Gli3) [15]. In
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the absence of Hh ligands, Ptch1 prevents the translocation of Smo to the primary cilia,
thereby inhibiting the nuclear localization of Gli and suppressing transcriptional activity.
Upon binding of Hh ligands to Ptch1, Smo suppression is abolished and downstream
pathway activity proceeds, resulting in nuclear translocation and activation of Gli.
Although the Hh ligand proteins all act as morphogens and have similar physiological
effects, each Hh ligand performs specialized functions due to the spatial and temporal
differences in their expression [16]. The Shh signaling pathway is a major regulator of
various processes, including cell differentiation and proliferation, and tissue polarity
[6,118]. Inhibition of Shh signaling is widely researched because aberrant Shh signaling
is a hallmark of many cancers [54,89,108]. This has been reported in many cancers,
including prostate, gallbladder, pancreatic, and basal cell carcinoma [62,65,66]. Basal cell
carcinoma (BCC) is the most common human cancer and is driven predominantly by the
hyper activation of the Hh pathway [75,85,119]. For this reason, a significant number of
BCC patients experience a clinical benefit from vismodegib (Erivedge®), a Smo inhibitor
approved by the US Food and Drug Administration (FDA) to treat metastatic or
reoccurring BCC [120]. In phase 2 trials in BCC patients, a majority experienced clinical
benefit with vismodegib treatment that included 30% of metastatic BCC patients
demonstrating a 30% decrease in visible tumor dimension, and 64% experiencing stable
tumor size. In patients with locally advanced BCC, 43% showed a 30% decrease in
visible tumor dimension, and 38% demonstrating stable tumor size. However, developed
resistance to vismodegib in up to 20% of advanced BCC patients within one year of
treatment represents a significant limitation [85,121]. Various studies have implicated
amino acid mutations in the vismodegib binding-site in Smo as a mechanism underlying

42
acquired resistance [85,122,123]. Due to adverse side effects and the potential for
acquired resistance to vismodegib there is a continued need to investigate novel
compounds that target the Hh signaling pathway, and identification of natural products
that act as Hh signaling inhibitors continues to be investigated [115,124-126].
Veratrum californicum (V. californicum) is native to the western United States
and is rich in steroidal alkaloids, including cyclopamine, veratramine, isorubijervine and
muldamine [6,24]. Of these alkaloids, the most notorious is cyclopamine, a teratogen
antagonist of the Shh signaling pathway [44]. Interest in V. californicum arose in the
1950s when unsettling high incidences of craniofacial birth defects in lambs were
observed by shepherds in Idaho. Numerous review articles have recounted the history of
scientific interest in the V. californicum, the efforts undertaken by researchers at the
Poisonous Plant Research Laboratory in Logan, UT to identify and validate the causative
agents of the observed birth defects, and the chronological order of the isolation and
structural elucidation of individual steroidal alkaloids [89,78,103]. However, few reports
in the literature have used modern, highly sensitive analytical techniques to examine the
full array of steroidal alkaloids in V. californicum [114]. Our lab has implemented
extraction techniques of the root and rhizome of V. californicum aimed at isolating these
steroidal alkaloids and characterizing their bioactivity towards Hh signaling using ShhLight II cell assays [114,103]. In the current study, we used ethanol extraction of the
leaves, stems and roots of V. californicum to determine if alkaloid ratios in the extract
yield synergistic amplification of Hh signaling suppression as compared to traditional
single alkaloid activity. The extracts were characterized using liquid chromatography and
high resolution electrospray ionization time of flight tandem mass spectrometry, and their
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biological activity was tested using Shh-Light II cells. The concentrations of
cyclopamine, veratramine, isorubijervine and muldamine were determined, and mixtures
of commercially available standards were prepared in the same ratios as found in the
extracts derived from the leaf, stem and root/rhizome of V. californicum. We sought to
test whether well-characterized steroidal alkaloids, at ratios consistent with native plant
content, exhibited a synergistic effect to inhibit Hh pathway signaling commensurate with
plant extract. Additionally, we sought to determine if additional alkaloids present in the
V. californicum contribute to Hh signaling inhibition. Earlier investigations of V.
californicum alkaloids may have failed to identify less abundant alkaloids that are
biologically significant and potentially valuable novel Hh pathway signaling antagonists.
3.4

Results

3.4.1 Qualitative Comparison of V. californicum Alkaloids by Plant Part
Qualitative variation is observed in the alkaloid composition of V. californicum by
plant part. The alkaloid profiles of the extracts from the leaf, stem and root/rhizome of V.
californicum are shown in Figure 3.1 a-c. Identification of each alkaloid peak was
achieved by high resolution mass spectrometry and verified by elution time compared to
commercially available standards. Data for most prominent peaks labelled in Figure 3.1
a-c including retention time, m/z, molecular formula (MF) and alkaloid identity are
summarized in Table 2. Mass spectra showing the m/z for each alkaloid used to estimate
molecular formulas listed in Table 2 are shown in Figure 3.2.
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Figure 3.1. Alkaloid chromatograms of V. californicum by plant part.
Chromatograms for extracts from the a) leaf, b) stem, and c) root/rhizome of V.
californicum. Common and unique alkaloids identified by MS are observed in each
extract. Labelled peaks correspond to the data summarized in Table 2. Extracted ion
chromatograms (EIC) are shown in d) and g) demonstrating the presence of veratramine
and cyclopamine isomers in stem and root/rhizome extracts, respectively. The total ion
chromatogram is shown in d) for the stem extract (black) and EIC (grey) generated using
the m/z window 410.3023 ± 0.01. The mass spectra for the peaks indicated by * in d) are
shown in e) and f). The total ion chromatogram is shown in g) for the root extract (black)
and the EIC (grey) generated m/z window 412.3186 ± 0.02. The mass spectra for the
peaks indicated by * in g) are shown in h-j).
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Figure 3.2.

Mass spectra data showing the m/z, retention time and source for each
alkaloid used to estimate molecular formulas listed in Table 2.
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Table 2.
Alkaloid list extracted from V. californicum leaf, stem and root.
Summary data of corresponding to the peaks identified in Figure 3.1 a-c.
Peak

m/z

Molecular Formula

Alkaloid

1

Retention Time
(min)
12.8

576.3836

C33H53NO7

N/A

2

13.9

572.3530

C33H49NO7

Veratrosine

3

14.6

574.3699

C33H51NO7

Cycloposine

4

14.9

414.3337

C27H43NO2

N/A1

5

15.7

430.3282

C27H43NO3

N/A

6

16.6

428.3136

C27H41NO3

N/A

7

16.7

576.3846

C33H53NO7

N/A

8

16.9

410.3021

C27H39NO2

Veratramine

9

17.4

410.3023

C27H39NO2

N/A2

10

18.7

412.3186

C27H41NO2

Cyclopamine

11

19.5

412.3184

C27H41NO2

N/A3

12

19.7

414.3342

C27H43NO2

Isorubijervine

13

21.1

458.3587

C29H47NO3

Muldamine

14

23.4

400.3550

C27H45NO

N/A

15

24.5

456.3446

C29H45NO3

N/A

Cyclopamine (Peak 10, m/z 412.3186) and veratramine (Peak 9, m/z 410.3023)
were observed in extracts from each of the three plant parts. Alkaloids present in extracts
from both the stem and leaf include cycloposine (Peak 3, m/z 574.3699) and veratrosine
(Peak 4, m/z 572.3530), which are glycosylated cyclopamine and veratramine,
respectively. Peak 1 is a glycosylated alkaloid observed only in stem extract, with an m/z
of 576.3836, corresponding to molecular formula C33H53NO7. In the stem and
root/rhizome extracts, isorubijervine (Peak 12, m/z 414.3342) and muldamine (Peak 13,
m/z 458.3587) are both observed.
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Peaks 4, 5, 6, 14 and 15 in Figure 3.1c correspond to unique alkaloids present
only in the root/rhizome extract. These alkaloids have m/z of 414.3337, 430.3282,
428.3136, 400.3550 and 456.3446 and correspond to the estimated molecular formulas of
C27H43NO2, C27H43NO3, C27H41NO3, C27H45NO and C29H45NO3, respectively. Potential
cyclopamine isomers were observed in the root extract, with a m/z consistent with
cyclopamine observed to elute with three distinct retention times. Figure 3.1g shows the
extracted ion chromatogram (EIC) for cyclopamine generated using the m/z window
412.3186 ± 0.02, and the corresponding mass spectra are shown in Figure 3.1h-j. Figure
3.1d shows the EIC for veratramine using the m/z window 410.3023 ± 0.01, and the
corresponding mass spectra are shown in Figure 3.1e-f.
3.4.2 Quantitative Analysis of V. californicum Alkaloids
Quantification of cyclopamine, veratramine, isorubijervine and muldamine in
alkaloid extracts were determined using charged aerosol detection and calibration curves
generated from commercially available standards, with values of R2 greater than 0.99.
Extractions were preformed three times, and alkaloid concentrations are shown by plant
part in Table 3 as mg of each alkaloid extracted per g of initial biomass ± the standard
deviation of the concentration observed in triplicate quantities. The quantity of
cyclopamine was determined to be 0.21 ± 0.02 mg/g, 3.23 ± 0.16 mg/g, and 7.38 ± 0.08
mg/g for the leaf, stem and root/rhizome, respectively.
Table 3.
Quantification of cyclopamine, veratramine, muldamine and
isorubijervine by plant part. Alkaloid quantities are reported as mg of alkaloid per
g of plant biomass.
Plant Part

Cyclopamine

Veratramine

Muldamine

Isorubijervine

Leaf

0.21±0.02

0.09±0.01

Not Detected

Not Detected
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Stem

3.23±0.16

1.33±0.13

0.36±0.06

1.00±0.08

Root/Rhizome

7.38±0.08

3.07±0.14

3.47±0.23

2.92±0.09

3.4.3 Bioactivity Evaluation of Combined Standards and Plant Extracts
Alkaloid standard mixtures were created using commercially available standards
in the same ratios as observed in the three plant parts. HPLC was used to validate that the
alkaloid standard mixtures matched the concentrations of the ethanolic extract, as is
shown for the root/rhizome extract and root standard mixture in Figure 3.3. The

Figure 3.3. HPLC Comparison of ethanolic root extract with root standard
mixture. a) ethanolic root extract and b) the root standard mixture, with each
commercially available alkaloid indicated as follows: v, veratramine; c, cyclopamine; i,
isorubijervine; and m, muldamine. Comparison of the HPLC chromatograms illustrates
the quantitative similarity in the concentrations of the alkaloids for which commercial
standards are available. Differences in bioactivity between these samples are due to the
additional alkaloids present in the extract.
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bioactivity of these alkaloid standard mixtures were quantified using Shh-Light II cells,
and compared to cyclopamine alone at the same concentration, and to V. californicum
extracts derived from leaf, stem, and root/rhizome of the plant. The treatment conditions
evaluating Hh signaling inhibition in Shh-Light II cells are summarized in Table 4 with
extracts and alkaloid standard mixtures normalized to cyclopamine concentrations of 0.5
and 0.1 µM, referred to as “high concentration” and “low concentration” treatments

Table 4.

Bioactivity treatment conditions for Shh-Light II cell assay.

Treatment Condition
Cyclopamine High
Leaf Standards High
Stem Standards High
Root Standards High
Cyclopamine Low
Leaf Standards Low
Stem Standards Low
Root Standards Low
Leaf Standards High - Cyc
Stem Standards High - Cyc
Root Standards High - Cyc

Cyclopamine
(μM)
0.5
0.5
0.5
0.5
0.1
0.1
0.1
0.1
0
0
0

Veratramine
(μM)
0
0.2
0.2
0.2
0
0.04
0.04
0.04
0.2
0.2
0.2

Muldamine
(μM)
0
0
0.15
0.2
0
0
0.03
0.04
0
0.15
0.2

Isorubijervine
(μM)
0
0
0.05
0.2
0
0
0.01
0.04
0
0.05
0.2

herein. The results of the biological assays are shown in Figure 3.4. There is no
significant difference between cyclopamine, the alkaloid standard mixtures, and the plant
extracts at high concentration treatments shown in Figure 3.4a. In the low concentration
treatments shown in Figure 3.4b, there is no significant difference observed between
cyclopamine standard, and the leaf standard mixture or the leaf extract, indicating that the
addition of 0.04 µM veratramine in the standard mixture did not enhance Hh signaling
inhibition. No difference is observed between the leaf extract at low concentration and
the corresponding combined standard cocktail.
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Figure 3.4. Bioactivity data for cyclopamine alone, the alkaloid standard
mixtures and the plant extracts at a) high concentration (0.5 µM) and b) low
concentration (0.1 µM). No significant difference was observed between treatment
conditions at high concentration. Statistically noteworthy differences were observed in
the low concentration treatments, and * indicates P < 0.05, and ** indicates P < 0.01. The
inhibitory activity of veratramine, isorubijervine and muldamine in the absence of
cyclopamine in the same concentrations as the high concentration treatment conditions is
shown in c).

The alkaloid standard mixtures of the stem and root/rhizome samples were
significantly different (P<0.05) than cyclopamine alone at the same concentration, with
relative Gli-reporter activity determined to 23.56 ± 1.86% and 20.59 ± 1.50% for the
stem and root/rhizome, respectively, compared to 36.31 ± 5.13% for 0.1 μM
cyclopamine. The inhibitory activity of these compounds was tested in the absence of
cyclopamine in the same concentrations as the high concentration treatment conditions,
and the results are shown Figure 3.4c. No Hh inhibition was shown for the leaf standards
mixture minus cyclopamine (0.2 μM veratramine), indicating that veratramine does not
inhibit the Hh signaling pathway. Modest Hh inhibition was demonstrated for the stem
and root/rhizome standard mixtures minus cyclopamine, indicating that isorubijervine
and muldamine demonstrate Hh antagonism.
There is a significant difference (P<0.01) between the stem and root/rhizome
extracts and their corresponding alkaloid standard mixtures, indicating that additional
alkaloids present in the extracts are capable of inhibiting Hh signaling.
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3.5

Discussion

The current investigation sought to achieve three objectives. The first was to
provide a detailed analysis of the alkaloid composition of V. californicum based on plant
part by performing a quantitative comparison of the alkaloids present in the leaf, stem
and root/rhizome of the plant. The second was to evaluate the potential synergistic
activity of cyclopamine, veratramine, isorubijervine and muldamine at ratios consistent
with alkaloids present in three plant parts, and determine if the alkaloid combinations
resulted in more effective Hh pathway antagonism than cyclopamine alone. The third was
to determine if additional alkaloids present in the extracts contribute to Hh signaling
inhibition by comparing the inhibitory potential of the plant extracts to alkaloid standard
mixtures with identical concentrations of cyclopamine, veratramine, isorubijervine and
muldamine.
Qualitative differences were observed in the alkaloid composition of V.
californicum by plant part. Using high resolution mass spectrometry, we identified
alkaloids that have previously been unreported for V. californicum. The molecular
formula and mass of Peak 1 is consistent with that expected for glycosylated
isorubijervine or etioline. Glycosylated etioline has previously been reported to be
present in the root of Solanum spirale [127]. Additional investigation would be required
to determine this definitely. Etioline is an intermediary in the biosynthetic pathway of
cyclopamine, and its presence in the extract would not be surprising [89]. Peak 4,
observed in only in the root/rhizome extract has a m/z and predicted molecular formula
consistent with etioline. In this study, potential cyclopamine isomers (see Figure 3.1g)
were observed in the root/rhizome extract analyzed by LC-MS. One of these potential
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cyclopamine isomers may be dihydroveratramine, which has previously been identified
in Veratrum album by Wilson, et al. [128]. However, the relative retention time between
dihydroveratramine and cyclopamine observed by Wilson, et al. does not support this
conclusion, because dihydroveratramine (RT: 13.66 min) was observed to elute prior to
cyclopamine (RT: 15.09 min), whereas the purported cyclopamine isomer observed in
this study elutes after cyclopamine (see Table 2) under similar HPLC conditions. No
naturally occurring isomers of cyclopamine have been previously observed in V.
californicum.
In Shh-Light II cells using the Dual-Glo® Luciferase Assay System, we evaluated
the inhibition of Hh signaling of cyclopamine alone, combinations of alkaloid standards,
and the inhibitory potential of extracts from each plant part. As shown in Figure 3.4a,
there is no significant difference between cyclopamine, the alkaloid standard mixtures,
and the plant extracts at high concentration treatments. There are trends that indicate
enhanced inhibition of alkaloid standard mixtures and extracts compared to cyclopamine
alone, but these do not amount to statistically significant differences. This result may be
due to low levels of Gli reporter activity observed in each treatment. However, as
demonstrated in Figure 3.4b, we determined that at the low concentration conditions,
addition of muldamine, veratramine and isorubijervine enhance Hh signaling inhibition
significantly in comparison to cyclopamine as demonstrated by the stem and
root/rhizome standard mixtures. Addition of veratramine to cyclopamine does not
enhance Hh signaling inhibition as demonstrated by the leaf standard mixture compared
to cyclopamine alone. By replicating concentrations of cyclopamine, veratramine,
isorubijervine and muldamine observed in plant extracts using commercially available
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standards and comparing the inhibitory potential of the plant extracts to alkaloid standard
mixtures, we determined that additional alkaloids present in the crude stem and
root/rhizome extracts inhibit Hh signaling. The alkaloids present in the leaf extract
include cycloposine, veratrosine, cyclopamine, veratramine, and the potential veratramine
isomer labeled Peak 8 in Figure 3.1. No difference is observed between the leaf extract at
low concentration and the corresponding combined standard mixture. This indicates that
cycloposine, veratrosine and Peak 8 do not contribute to Hh signaling inhibition in this
model system. However, it has been proposed that hydrolysis of the glycosidic linkage in
glycosylated alkaloids during digestion contributes to the teratogenic effects of V.
californicum alkaloids when consumed by foraging sheep [38]. Furthermore, no
significant difference is observed between cyclopamine alone, the leaf standard mixture
or the leaf extract, indicating that the addition of 0.04 µM veratramine in the standard
mixture, or the additional alkaloids present in the leaf extract did not enhance Hh
signaling inhibition. We observed a significant difference between the alkaloid standard
mixtures of the stem and root/rhizome samples to that of cyclopamine, indicating the
addition of veratramine, isorubijervine and muldamine enhance Hh inhibition. However,
the modest enhancement of Hh inhibition seems to be additive rather than synergistic,
with the addition of these alkaloids providing more, albeit weakly inhibitory effects. No
Hh inhibition was demonstrated for 0.2 μM veratramine in the leaf standard minus
cyclopamine treatment, indicating veratramine does not inhibit the Hh signaling pathway.
This corroborates feeding trials in which veratramine was shown to cause teratogenic
malformations in sheep distinct from the cyclopia, such as hypermobility of the knee
joints leading to bow-legged lambs unable to stand [129]. The stem and root/rhizome
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standard mixtures containing veratramine, isorubijervine and muldamine indicate that
muldamine and/or isorubijervine inhibit the Hh pathway. Muldamine has been shown to
result in craniofacial defects in hamsters in feeding studies that may be attributed to
interruption of normal Hh signaling [105]. Further investigation to isolate, characterize,
and assess the bioactivity of individual, less abundant alkaloids present in the stem and
root/rhizome extracts is underway.
3.6

Materials and Methods

3.6.1 Chemicals and Solvents
Cyclopamine was purchased from Alfa Aesar (Ward Hill, MA), veratramine was
purchased from Abcam Biotechnology Company (Cambridge, United Kingdom), and
isorubijervine and muldamine were purchased from Logan Natural Products (Plano, TX).
Extraction and purification solvents, 95% ethanol, ammonium hydroxide and chloroform
were purchased from Fisher Scientific (Pittsburgh, Pennsylvania). High performance
liquid chromatography (HPLC) mobile phases included 0.1% formic acid and HPLC
grade acetonitrile (>99% purity, Fisher Scientific).
3.6.2 Sample Extraction and Preparation
A complete specimen of V. californicum was harvested in the Boise National
Forest, Idaho at an elevation of 2134 m. The leaf, stem and roots/rhizomes of the plant
were separated, and all plant parts were cut into smaller pieces to fit into quart size
sealable bags. The specimens were placed in a cooler on a bed of ice for transportation.
The biomass was collected at a late stage in the plant’s life cycle; the plant had noticeable
brown edges along its leaves and top indicating annual deterioration of above ground
material in preparation for winter. Within two hours and upon arrival in the lab, the plant
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material was chopped into 2 cm segments and dried for 14 hrs. using a LabConco
Freezone 4.5 freeze drying unit, followed by storage at -20 ºC. The biomass was flash
frozen in liquid nitrogen, and pulverized into a fine powder using a mortar and pestle.
Approximately 2.0 g of powdered biomass was added to a 250 mL round bottom flask
followed by 100 mL of 95% ethanol. The resultant slurry was sonicated for 1 hr. and then
agitated for 24 hrs. on a stir plate. The biomass was removed by vacuum filtration
(Whatman filter paper, 0.45 μm), and solvent removed by rotary evaporation. The dried
crude extract was dissolved in 10 mL of ethanol, and the solution was warmed to 40 ºC
and sonicated to achieve complete dissolution. Addition of 35% aqueous ammonia
achieved alkaline solvent conditions (pH ≥10). The aqueous alkaline solution was added
directly to a supported liquid extraction (SLE) column (Chem Elut, Agilent, Santa Clara,
California) and allowed to adsorb for 10 min., followed by elution of alkaloids with
chloroform (3×10 mL) using a vacuum manifold set to a pressure of 2 mbar. The
chloroform fractions were combined, filtered, and evaporated to dryness. All samples
were dissolved in 1 mL ethanol as a mixture of alkaloids.
3.6.3 Alkaloid Quantification
The concentrations of cyclopamine, veratramine, isorubijervine and muldamine in
alkaloid extracts were determined by Thermo Scientific UltiMate 3000 HPLC equipped
with a Corona Veo RS charge aerosol detector (CAD) and MSQ Plus mass spectrometer
(MS). HPLC separation of alkaloids was achieved using a Thermo Acclaim 120 C18
column (2.1 × 150 mm, 3 µm), and mobile phases consisting of 0.1% formic acid (v/v) in
water (Buffer A) and 0.1% formic acid (v/v) in acetonitrile (Buffer B) with a flow rate of
0.3 ml/min. A linear gradient method beginning at 95% Buffer A and 5% Buffer B, up to
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60% Buffer B over a 25 min. run time achieved desired separation of alkaloids from the
extracts. Cyclopamine, veratramine, isorubijervine and muldamine standards were used
to create a calibration curve at concentrations of 0.1, 0.5, 1.0, 5.0 and 10.0 mM with
detection recorded by a CAD with the power function set to pA 1.70. The quantity of
these alkaloids were determined from the alkaloid mixtures obtained from the leaf, stem
and root extracts in triplicate.
3.6.4 Alkaloid Identification
In order to identify the steroidal alkaloids in V. californicum leaf, stem and
root/rhizome extracts, samples were analyzed by HPLC-MS, where the mass
spectrometer was an ultra-high resolution Quadrupole Time of Flight (QTOF) instrument
(Bruker maXis). The electrospray ionization (ESI) source was operated under the
following conditions: positive ion mode, 1.2 bar nebulizer pressure, 8 L/min flow of N2
drying gas heated to a temperature of 200 °C, 3000 V to -500 V voltage between HV
capillary and HV end-plate offset, mass range set from 80 to 800 m/z, and the quadrupole
ion energy at 4.0 eV. Sodium formate was used to calibrate the system in this mass range
of 80 to 800 m/z. HPLC separation was achieved using a XTerra MS C18 column, 3.5 μm,
2.1 x 150 mm (Waters, Milford, MA). The flow rate was 250 μL/min. The mobile phases
were 5% acetonitrile and 0.1% formic acid in water (Buffer A) and acetonitrile and 0.1%
formic acid (Buffer B). The linear gradient method was used to separate analytes starting
at 5% Buffer B and increasing to 60% Buffer B over 25 min. A 1 μL sample injection
was used. Data were analyzed with the Compass Data Analysis software package (Bruker
Corporation, Billerica, Massachusetts).
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3.6.5 Cell Culture
Shh-Light II cells (JHU-068) were maintained in Dulbecco's Modified Eagle
Medium (DMEM) (Gibco) supplemented with 0.4 mg/mL geneticin, 0.15 mg/mL
Zeocin™ (Invitrogen), and 10% bovine calf serum. The cells were grown at 37°C in an
atmosphere of 5% CO2 in air and 100% relative humidity. This mouse embryonal NIH
3T3 cell line contains a stably transfected luciferase reporter with eight copies of the
consensus Gli binding site [116]. Alkaloid treatment conditions were dissolved in
ethanol and added to DMEM media containing 0.5% bovine calf serum.
3.6.6 Biological Assays
Shh-Light II cells were seeded in a 96-well plate and grown to complete
confluence in the media described above. When cells were confluent, the media was
replaced with DMEM supplemented with 0.5% bovine calf serum, and treated with 0.1
ng of N-terminal mouse recombinant Shh (R&D Systems, Minneapolis, Minnesota)
dissolved in DMEM, and select alkaloid treatment. In each experiment, the controls and
treatment wells contained all vehicles, with a final ethanol concentration of 0.05%. Gli
activity in the Shh-Light II cell line was assayed 48 hrs. after treatment with Shh protein
and select compounds using the Dual-Luciferase Reporter Assay System (Promega,
Madison, Wisconsin). The Gli-activity was measured by luminescence emitted from cells
using a BioTek Synergy H1m Microplate reader. The Gli-activity determined in the
biological assay is presented as a relative response ratio (RRR) as described in the DualLuciferase Reporter Assay System manual. Each experiment was performed thrice.
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CHAPTER FOUR: STEROIDAL ALKALOID VARIATION IN VERATRUM
CALIFORNICUM AS DETERMINED BY MODERN METHODS OF ANALYTICAL
ANALYSIS

Picture 3.
Graphical abstract form “Steroidal alkaloid variation in Veratrum
californicum as determined by modern methods of analytical analysis”
4.1

Foreword

The following chapter is based on a manuscript published in the journal
Fitoterapia in 2019 [130]. This study was conducted using modern analytical methods
and state-of-the-art instrumentation, and presents the ratio of steroidal alkaloids present in
the aerial and root/rhizome of Veratrum californicum collected from two different growth
plots throughout the growth cycle of the plants. This study further identifies the presence
of Veratrum californicum steroidal alkaloids that have yet to be characterized.
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4.2

Abstract

Veratrum californicum is a rich source of steroidal alkaloids, many of which have
proven to be antagonists of the Hedgehog (Hh) signaling pathway that becomes aberrant
in over twenty types of cancer. These alkaloids first became known in the 1950’s due to
their teratogenic properties, which resulted in newborn and fetal lambs developing
cyclopia as a result of pregnant ewes consuming Veratrum californicum. It was
discovered that the alkaloids in V. californicum were concentrated in the root and
rhizome of the plant with much lower amounts of the most active alkaloid, cyclopamine,
present in the aerial plant, especially in the late growth season. Inspired by the limitations
in analytical instrumentation and methods available to researchers at the time of the
original investigation, we have used state-of-the-art instrumentation and modern
analytical methods to quantitate four steroidal alkaloids based on study parameters
including plant part, harvest location, and growth stage. The results of the current inquiry
detail differences in alkaloid composition based on the study parameters, provide a
detailed assessment for alkaloids that have been characterized previously (cyclopamine,
veratramine, muldamine and isorubijervine), and identify at least six alkaloids that have
not been previously characterized. This study provides insight into optimal harvest time,
plant growth stage, harvest location, and plant part required to isolate, yet to be
characterized, alkaloids of interest for exploration as Hh pathway antagonists with
desirable medicinal properties.
4.3

Introduction

Congenital malformations in lambs were observed in alarming frequency during
the first half of the 20th century in south-western Idaho, and beginning in 1956 a detailed
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study of the malformed lamb problem was undertaken by researchers from the United
States Department of Agriculture [131]. The affected lambs were commonly called
“monkey-faced,” and were observed to have head deformities that included complete
cyclopia, hydrocephalus, harelip, cleft palate, and displacement of the nose. Observations
by ranchers with affected animals implicated mountain ranges with altitudes up to 10,000
feet containing alpine meadows used for grazing during the breeding season, typically in
early August. Controlled breeding experiments determined the congenital anomaly was
not due to genetic factors, and potential environmental elements including an excess or
deficiency of nutritional factors, toxic mineral elements, or the presence of poisonous
plants were assumed to underlie the observation. Field studies determined that
deformities occurred in lambs from ewes that grazed during the latter part of the summer
in wet seepage meadows above 6,000 feet in elevation, locations where Veratrum
californicum is commonly encountered [31]. Subsequent controlled feeding trials of fresh
and dried green V. californicum reproduced the deformities observed in the field, and
validated the teratogenic role of V. californicum [33]. Following the confirmation that
ingestion of V. californicum by pregnant ewes was responsible for the observed
malformations, attention was turned toward the isolation and characterization of
teratogenic compounds underlying the phenomenon of fetal malformation [34]. The
teratogenic material was speculated to be steroidal alkaloids, either in the form of
glycosidic derivatives or the parent alkamine. The compound responsible for the
cyclopian malformations was found and given the trivial name cyclopamine [132].
Benzene extraction of V. californicum root and subsequent separation with paper
chromatography revealed eight to ten unique alkaloids. In order to purify adequate
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quantities of alkaloids for additional chemical characterization, recrystallization of crude
benzene extracts from acetone-water and methanol-water allowed for the enrichment of
three alkaloids –veratramine, cyclopamine and an unknown compound designated as
alkaloid Q.
Feeding experiments and field observations suggested that significant variation
was observed in the teratogenic effect of V. californicum on lambs that consumed the
plant at differing growth sites and growing periods [133]. The content of cyclopamine as
a function of plant part, stage of growth, and growth location was undertaken by Keeler
and Binns circa 1970. In their study, benzene soluble steroidal alkaloids were isolated
and total alkaloid concentrations were determined by measuring turbidity following
treatment with Mayer reagent, and the concentrations of individual alkaloids were
assigned based upon densitometry on photographed thin layer chromatography (TLC)
plates. The TLC measurements separated three principal benzene soluble alkaloids:
cyclopamine, veratramine, and alkaloid Q. The level of cyclopamine varied considerably
between collection sites and stage of growth. Generally, it was determined that the
concentration of cyclopamine was highest in the early growth season in the leaves, and in
the late growing season in the root/rhizome. The structure of alkaloid Q was later
elucidated, and was given the trivial name, muldamine [134].
Decades after the observation of the malformed lambs led to the isolation and
characterization of cyclopamine, the teratogenic mechanism of cyclopamine was
determined to be inhibition of the Hedgehog (Hh) signaling pathway [44]. The Hh
signaling pathway is required for proper development of all animals containing bilateral
symmetry and guides the formation of hands and feet, the central nervous system, and
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most epithelial tissues [16,135-137]. In mammals, the mechanism of the Hh signaling
begins with the binding of one of three secreted ligands; Sonic hedgehog (Shh), Desert
hedgehog (Dhh) or Indian hedgehog (Ihh) to the transmembrane transporter protein
Patched (Ptch) [17]. Ptch, when not bound to one of these Hh ligands, inhibits the seventransmembrane protein Smoothened (Smo), a G protein-coupled-like receptor. Upon
binding with Hh ligands, this inhibition is inactivated, and a signaling cascade originating
at Smo begins; the pathway culminates in the activation of the Gli family of zinc-finger
transcription factors in vertebrates. The Gli transcription factors (particularly Gli-1 and
Gli-2) up-regulate the transcription of Hh target genes, which enhance cellular
proliferation and the epithelial-mesenchymal transition [5,138-140]. Although normal to
development and several adult somatic processes, Hh signaling has been demonstrated to
contribute to the pathogenesis of over twenty cancers, and is exceedingly active in basal
cell carcinoma (BCC) [89]. The medicinal properties and potential for discovery of
therapeutic compounds, like those found in V. californicum, are the reason considerable
interest persists in the identification of novel Hh signal inhibitors, including those
isolated from natural sources [115,124-125].
Few reports in the literature have used modern, highly sensitive analytical
techniques to examine the full array of steroidal alkaloids in V. californicum. Our lab has
surveyed and optimized steroidal alkaloid extraction conditions and employed state-ofthe-art analytical instrumentation leading to identification of less abundant alkaloids
present in V. californicum extracts [114]. We have also correlated extraction methods
with teratogenic properties using Shh-Light II cell assays to determine how isolation of
alkaloids using different chemical treatments alters the potency of cyclopamine [103].
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Recently, our lab demonstrated that uncharacterized alkaloids present in V. californicum
inhibit the Hh signaling pathway by comparing commercially available alkaloid standards
to alkaloids extracted from plant specimens [117]. We first determined the concentration
of four commercially available alkaloids −cyclopamine, veratramine, muldamine and
isorubijervine− present in the ethanolic extract of V. californicum, replicated the
concentration of those alkaloids observed in the crude extract in a cocktail from
commercially available standards, and compared the inhibitory effect of crude extracts to
the mixture of alkaloid standards. Using Shh Light II cells and a luminescence based
assay, significant differences were observed for Hh pathway inhibition between the stem
and root/rhizome extracts and their corresponding alkaloid standard mixtures, indicating
that uncharacterized alkaloids present in plant extracts contribute to Hh signaling
inhibition. In the current study, we quantify the amounts of four steroidal alkaloids
−cyclopamine, veratramine, muldamine and isorubijervine− in V. californicum as a
function of plant part, growth cycle and collection location. The molecular structures of
the alkaloids quantified in this study are shown in Figure 2.2. In addition to providing
quantitative data for these four compounds, we provide a qualitative examination of the
chemical diversity of alkaloids present in V. californicum. At least six alkaloids with
unique molecular weight, molecular formula, and identity are reported, constituting
potential drug targets for Hedgehog pathway inhibition.
4.4

Materials and Methods

4.4.1 Materials
Plants were gathered from alpine meadows in the Boise National Forest in 2014
and stored in a freezer. All solvents were purchased from commercial sources and used
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without further purification. The solvents used were ethanol (95%), chloroform (HPLC
grade), formic acid (MS grade), ammonium hydroxide (30% in water), and acetonitrile
(HPLC grade), all obtained from Fischer Scientific (Hampton, NH, USA).
4.4.2 Plant collection
Plants were harvested from two stands of V. californicum near the Bogus Basin
Mountain Resort, Boise National Forest, Idaho, USA. V. californicum, also known as
California false hellebore, grows up to 2 m in height, has cornstalk-like stems and has
large, broad elliptical leaves [141,142]. Plants were harvested at 6901 feet, elevation
(N43 45.719” W 116 05.327”) beside the Shindig Trail, and at 7066 feet elevation (N43
45.858” W 116 05.090”) beside the Elk Meadows Trail. In each location, three to five
full plants were harvested; the rhizome and aerial plant were separated, and transported
on ice to the lab. Once in lab, plant parts were diced, followed by drying with a
LabConco Freezone 4.5 freeze drying unit (Labconco Corporation, Kansas City, MO,
USA), before being stored at -20ºC. Plants were harvested on May 23, 2014, July 3,
2014, and September 5, 2014 at both locations.
4.4.3 Biomass preparation
To prepare for extraction, the biomass was removed from the freezer, cut into
even smaller pieces (1-2 cm cubes) and placed in a lyophilizer for 24-48 hours to ensure
dryness. Once dried the samples were submerged in liquid nitrogen, and crushed to a
fine powder by mortar and pestle.
4.4.4 Alkaloid extraction
Approximately 2.0 g of powdered biomass was added to 100 mL of 95% ethanol
and the mixture was placed in a sonicator for 30 min, followed by agitation for 24 hrs. on
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a stir plate. The plant material was separated from the solvent by vacuum filtration
(Whatman filter paper, 0.45 µm), and the solid material discarded. The ethanol was
removed by rotary evaporation to yield the crude alkaloids. The alkaloids were dissolved
in 10 mL of 95% ethanol, and the solution was warmed to 40 ºC and sonicated to achieve
complete dissolution. Addition of 35% aqueous ammonia achieved alkaline solvent
conditions (pH ≥ 10). The alkaline solution was added directly to a supported liquid
extraction (SLE) column (ChemElut, Agilent, Santa Clara, CA, USA) and allowed to
adsorb for 10 min, followed by elution of alkaloids with chloroform (3 × 10 mL) using a
vacuum manifold set to a pressure of 2 mbar. The chloroform fractions were combined,
filtered, and evaporated to dryness. All samples were dissolved in 1 mL of 100% ethanol
as a mixture of alkaloids.
4.4.5 Alkaloid Quantification
The concentrations of cyclopamine, veratramine, isorubijervine and muldamine in
alkaloid extracts were determined using an UltiMate 3000 uHPLC (Thermo Scientific,
Waltham, MA, USA) equipped with a Corona Veo RS charged aerosol detector (CAD)
and MSQ Plus mass spectrometer (MS). HPLC separation of alkaloids was achieved
using a Thermo Acclaim 120 C18 column (2.1 × 150 mm, 3 µm), and mobile phases
consisting of 0.1% formic acid (v/v) in water (Buffer A) and 0.1% formic acid (v/v) in
acetonitrile (Buffer B) with a flow rate of 0.3 mL/min. A linear gradient method
beginning at 95% Buffer A and 5% Buffer B, up to 60% Buffer B over a 25 min. run time
achieved desired separation of alkaloids from the extracts. Cyclopamine (Alfa Aesar,
Ward Hill, MA, USA, >99% purity), veratramine (Abcam Biotechnology Company,
Cambridge, UK, >98% purity), isorubijervine (Logan Natural Products, Plano, TX, USA,
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99% purity) and muldamine (Logan Natural Products, Plano, TX, USA, 99% purity)
standards were used to create a calibration curve at concentrations of 0.1, 0.5, 1.0, 5.0 and
10.0 mM with detection recorded by CAD with the power function set to pA 1.70.
Calibration curves were generated in triplicate for each alkaloid at each of the five
alkaloid concentrations. The quantities of these alkaloids were determined from the
alkaloid mixtures obtained from the aerial and root/rhizome extracts in triplicate.
Quantification was achieved using an intra-lab validated HPLC method. Limits of
detection and limits of quantification were determined from the slope and the standard
deviation observed from linear calibration curves.
4.4.6 Alkaloid Identification
To identify the steroidal alkaloids in V. californicum aerial and root/rhizome
extracts, samples were analyzed by HPLC-MS, where the mass spectrometer was an
ultra-high resolution Quadrupole Time of Flight (QTOF) instrument (Bruker maXis,
Billerica, MA, USA). The electrospray ionization (ESI) source was operated under the
following conditions: positive ion mode, 1.2 bar nebulizer pressure, 8 L/min flow of N2
drying gas heated to a temperature of 200 °C, 3000 V to −500 V voltage between HV
capillary and HV end-plate offset, mass range set from 80 to 800 m/z, and the quadrupole
ion energy at 4.0 eV. Sodium formate was used to calibrate the system in this mass range.
HPLC separation was achieved using a XTerra MS C18 column, 3.5 µm, 2.1 × 150 mm
(Waters, Milford, MA, USA). The flow rate was 250 µL/min. The mobile phases were
5% acetonitrile and 0.1% formic acid in water (Buffer A) and acetonitrile and 0.1%
formic acid (Buffer B). The linear gradient method was used to separate analytes starting
at 5% Buffer B and increasing to 60% Buffer B over 25 min. A 1 µL sample injection
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volume was used. Data were analyzed with the Compass Data Analysis software package
(Bruker Corporation).
4.5

Results

Figure 4.1. Chromatograms of alkaloids extracted from above-ground and belowground V. californicum from two collection sites. Elk Meadows (a-f) and Shindig (g-l)
collection sites from aerial and roots/rhizomes of V. californicum. Common and unique
alkaloids identified by MS are observed in each extract. Labeled peaks correspond to the
data summarized in Table 5. The chromatograms displayed were generated as base peak
chromatograms from data acquired on a Q-TOF mass spectrometer.
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Qualitative variation was observed in the alkaloid composition of V. californicum
by plant part, growth stage, and harvest location, as shown in the alkaloid profiles of the
extracts in Figure 4.1 a-l. Identification of each alkaloid peak was achieved by high
resolution mass spectrometry and verified by elution time compared to commercially
available standards. Data for the peaks labelled in Figure 4.1 a-l, including retention time,
m/z, molecular formula (MF) and alkaloid identity are summarized in Table 5.
Table 5.
Peak
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

Summary data corresponding to the peaks identified in Figure 4.1.
Retention Time
(min)
18.6
20.0
21.1
21.5
22.3
22.7
23.2
23.6
24.7
26.5
27.2
27.6
28.1
29.4
29.8
30.2

m/z
576.396
572.365
574.381
414.342
430.337
574.381
428.320
576.397
410.312
412.326
410.311
412.326
414.343
416.357
458.370
398.347

Estimated
Molecular Formula
C33H53NO7
C33H49NO7
C33H51NO7
C27H43NO2
C27H43NO3
C33H51NO7
C33H53NO7
C33H53NO7
C27H39NO2
C27H41NO2
C27H39NO2
C27H41NO2
C27H43NO2
C27H45NO2
C29H47NO3
C27H43NO

Alkaloid
N/A
Veratrosine
Cycloposine
Etioline?
Tetrahydrojervine?
N/A
Dihyrdojervine?
N/A
Veratramine
Cyclopamine
N/A
N/A
Isorubijervine
22-keto-26-aminocholesterol?
Muldamine
Verazine?

Mass spectra for peaks 1-16 are presented in Figure 4.3, showing the retention time and
m/z used to estimate molecular formulas provided in Table 5. Figure 4.2 shows
quantitative determination of the four common Veratrum alkaloids cyclopamine,
veratramine, isorubijervine, and muldamine for which commercially available standards
were available to obtain calibration curves and accurately determine alkaloid quantity. In
general, significantly higher alkaloid concentrations and alkaloid diversity are observed
in the root/rhizomes in both locations as compared to the aerial plant. Alkaloid
concentration is given as mg alkaloid per g of biomass used for extraction, and the

69
standard deviation for triplicate sampling is shown. During each collection a minimum of
three plant samples were collected and the standard deviation primarily reflects variation
in alkaloid concentrations observed between individual plants, and to a lesser extent
technical variation in extraction efficiency. The limit of quantification was determined
0.011, 0.011, 0.010 and 0.015 mg/g for cyclopamine, veratramine, muldamine and
isorubijervine, respectively; and the limit of detection was determined to be 0.003, 0.003,
0.003 and 0.005 mg/g for cyclopamine, veratramine, muldamine and isorubijervine,
respectively.

Figure 4.2.
Quantification of alkaloids from both harvest sites for aerial and
below ground V. californicum. Alkaloid concentration is presented as mg alkaloid per g
of plant biomass extracted. Significantly higher concentrations were observed in the
below ground plant as compared to the aerial plant. Quantification data was generated
using charged aerosol detection and calibration curves created from commercially
available alkaloid standards.
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Figure 4.3.
Mass spectra from the peaks identified from Figure 4.1 used to
generate the data in Table 5. Included is the retention time (RT) and sample from which
the MS data was taken. MS data was acquired using an ultra-high resolution Q-TOF mass
spectrometer with mass error <5 ppm.
4.5.1 Root/rhizome alkaloid variation
Specimens collected from the Elk Meadows site showed the highest concentration
of cyclopamine in the root/rhizome collected in the early season, May 2014, with
8.69±1.17 mg/g extracted; whereas the July and September collections yielded 4.14±0.50
mg/g and 5.01±0.50 mg/g, respectively. Interestingly, collections from the Shindig site
showed the lowest rhizome concentration of cyclopamine in May at 5.20±1.02 mg/g,
with significantly higher concentrations observed in July and September, at 11.01±1.02
mg/g and 9.39±1.85 mg/g, respectively. From the Shindig location, a fluctuation in
rhizome alkaloid concentration was observed for veratramine similar to that of
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cyclopamine, with the highest concentration observed in July at 15.35±2.86 mg/g, and
6.16±1.03 mg/g and 5.57±2.60 mg/g for May and September, respectively. Strangely, the
concentration of veratramine was much lower throughout the growth season in the
samples collected from Elk Meadows, with the greatest concentration observed in July at
1.98±0.20 mg/g, and 1.06±0.48 mg/g 1.63±0.16 mg/g observed for May and September,
respectively.
From both harvest locations, muldamine and isorubijervine were less abundant in
the root/rhizome than either cyclopamine or veratramine. From Elk Meadows,
isorubijervine was detected above the quantification limit from each sampling period,
with the greatest abundance of 1.12±0.12 mg/g in September, and the lowest abundance
in May at 0.44±0.19 mg/g. However, from the Shindig location, only the May extract
yielded a quantifiable amount of isorubijervine, measured at 0.91±0.39 mg/g. However,
qualitative detection of isorubijervine was observed below quantification limit from the
Shindig site for both the July and September collection times. From both locations,
muldamine was only present above the limit of quantification in the July and September
extracts. From Elk Meadows, muldamine was not detected in the May sample, and was
determined to be 0.21±0.09 and 0.10±0.08 mg/g for the July and September samples,
respectively. The high standard deviation relative to the concentrations determined
reflects that observed concentrations varied significantly between plant extracts. For the
July extracts, muldamine was only detected above the limit of quantification in two of the
three samples analyzed, and only one of three for the September extracts. From Shindig,
muldamine was detected in all the extracts, although it was below the limit of detection
for May, and July and September yielded 0.48±0.20 mg/g and 0.48±0.42 mg/g,
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respectively. Again, concentrations varied considerably between individual plants, with
muldamine only detected above the limit of quantification in two of the three samples
analyzed for July and one of three for September.
4.5.2 Aerial plant alkaloid variation
In the aerial plant at both harvest locations, the concentration of each alkaloid
quantified was highest in May, and was observed to decrease progressively throughout
the growth season. For the Elk Meadow location, concentrations of cyclopamine varied
from 0.28±0.10 mg/g in May to 0.03±0.00 mg/g in September, while at the Shindig site
concentrations varied from 0.10±0.01 mg/g in May to 0.04±0.00 mg/g in September.
Veratramine concentrations at the Elk Meadows plot varied between 0.34±0.07 mg/g in
May and 0.02±00 mg/g in September, and for the Shindig site, veratramine levels were
determined to be 0.05±0.00 in May and 0.02±0.00 mg/g in September. Muldamine was
either not detected or below the quantification limit in the aerial plant from both locations
and during each collection period. Relatively high levels of isorubijervine were detected
in the aerial plant in May at both sites, and were determined to be 0.28±0.09 and
0.07±0.01 mg/g for Elk Meadows and Shindig, respectively. These levels were not
sustained through the growth season, as all other measurements were below the limit of
quantification, or were not detected.
4.6

Discussion

The current investigation sought to explore the diversity of alkaloids from V.
californicum by plant part, location, and growth stage. In order to provide a detailed
analysis of the alkaloid composition of V. californicum based on plant part, a quantitative
comparison of four alkaloids was performed for –cyclopamine, veratramine,
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isorubijervine and muldamine– present in the aerial portion and root/rhizome of the plant.
The generation of Figures 4.1 and 4.2, and the data presented in Table 5, consisted of
analysis of 36 separate Veratrum samples. For each data point, three independent plant
samples were harvested, solvent extracted, and analyzed by HPLC. The harvest sites
were within 200 ft elevation difference, and both locations were wet, mucky, and
naturally spring fed. Elk Meadows faces west, while Shindig faces east, so sun exposure
is different between the two harvest sites.
The magnitude of cyclopamine accumulated in V. californicum tissues reported in
this study is consistent with recent reports [103,143]. The observation by Augustin et al.
that cyclopamine accumulates in the rhizome of the plant during the growth season is
consistent with our analysis for the below ground plant at the Shindig location, in which
May collections contained 5.20±1.02 mg/g, and September collection yielded 9.39±1.85
mg/g, an increase of ~81% over the growth season. Augustin et al. speculated that this
increase, along with higher expression of biosynthetic genes in the below ground plant,
indicates that cyclopamine biosynthesis occurs in the underground organs of the plant.
However, from the Elk Meadows location, we observed a modest decrease in
cyclopamine concentration over the growth season, with the highest value found in May
of 8.69±1.17 mg/g, decreasing to 5.01±0.50 mg/g in September, a decrease of ~42%. The
reason for the discrepancy in cyclopamine accumulation is unclear. Modest fluctuations
were observed in below ground abundance of the other alkaloids analyzed as well. From
the Elk Meadows location, veratramine increased over the course of the growth season
from a low in May, the highest level observed in July, and then a modest decrease in
September. Similarly from the Shindig location the greatest abundance of veratramine
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was observed in July. However, the amount of veratramine at this time point was 7.8X
greater from the Shindig location compared to the Elk Meadows location, with values of
15.35±2.86 mg/g and 1.98±0.20 mg/g observed from each location, respectively. From
the Elk Meadows location, the content of isorubijervine increased slightly over the
growth season but remained relatively low, whereas from the Shindig location
isorubijervine was only quantifiable from the May collection. Muldamine remained
relatively low in abundance from both locations, below or near the quantification and
detection limit. In summary, alkaloid abundance and the fluctuations in alkaloid content
varied considerably between collection sites. This is consistent with the findings of
Keeler and Binns in their original evaluation of alkaloid content by growth stage, and is
consistent with the variable teratogenic effect observed in controlled feeding trials [133].
Consistent with prior analysis of Veratrum alkaloid content sampled throughout
the growth season, the bar graphs detailed in Figure 4.2 show that aerial alkaloid
quantities decrease from early season through late growth phase for the plants [133,143].
This was consistent for both locations and for all of the alkaloids quantified. Plants
harvested from Elk Meadows retained ~6% of their original alkaloid content from May to
September, while the Shindig aerial plants retained closer to ~27% alkaloid content.
However, it is worth noting that while the quantities of cyclopamine and veratramine
decreased throughout the growth season, the amount of their glycosylated derivatives –
cycloposine and veratrosine– increased throughout the growth season. This suggests
conversion to the glycosylated derivatives occurs during the growth season.
Qualitative differences in the alkaloid diversity are observed by plant part. The
diversity of alkaloids present in the aerial plant is significantly lower than the alkaloid
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diversity of the root and rhizome for the same plants. As is shown in Figure 4.1 and
Table 5, mass spectrometry analysis identified 16 molecular ion peaks that yielded
estimated molecular formulas consistent with steroidal alkaloids. Using high resolution
mass spectrometry and verified by elution time compared to commercially available
standards, Peaks 9, 10, 13, and 15 were definitively identified as veratramine,
cyclopamine, isorubijervine, and muldamine, respectively (Figure 4.1). Peaks 2 and 3
were identified as veratrosine and cycloposine based on the comparison of the accurate
and exact mass for these compounds, and the high degree of mass accuracy of our Q-TOF
system (mass error <5 ppm). Peak 16, with m/z of 398.347 and predicted molecular
formula of C27H43NO is likely verazine, an important intermediate in the cyclopamine
biosynthetic pathway [143]. Similarly, Peak 4, with m/z of 414.342 and predicted
molecular formula of C27H43NO2 is suspected to be etioline, which is an intermediary in
the biosynthetic pathway of cyclopamine, and its presence in the extract is expected [89].
Peak 15, with an m/z of 416.357 and an estimated molecular formula of C27H45NO2 may
be the cyclopamine biosynthetic intermediate 22-keto-26-aminocholesterol; definitive
determination of this suspected assignment will require additional investigation [143].
Peaks 1 and 8 had the same m/z of 576.396, and estimated molecular formula,
C33H53NO7, indicating they may be isomers of one another due to the significantly
difference in retention time observed by chromatographic separation. This molecular
formula and variation in chromatographic retention time are consistent with glycosylated
isorubijervine and etioline. Peaks 5 and 7 have m/z of 430.337 and 428.320, and
estimated molecular formulas of C27H43NO3 and C27H41NO3. These may be
tetrahydrojervine and dihydrojervine, respectively, as described previously [144].
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Additionally, potential isomers of both veratramine and cyclopamine were observed as
Peaks 11 and 12, respectively, with identical m/z and estimate molecular formulas, but
distinct retention times for each. These compounds may be of significant biological
interest, and the isolation and structural characterization of each is currently underway in
our laboratory.
4.7

Conclusion

Veratrum californicum is a rich source of steroidal alkaloids including inhibitors
of the Hedgehog signaling pathway. Although the two collection sites used in this study
were relatively close together and the elevation difference between the two was not
significant, quantitative variation in alkaloid amount and qualitative variation in alkaloid
diversity were observed between the two sites. Additionally, considerable variation was
observed between individual plants, as indicated by the relatively high standard deviation
observed between triplicate biological replicates. This study provides insight into optimal
harvest time, plant growth stage, harvest location, and plant part required to isolate, yet to
be characterized, alkaloids of interest for exploration as Hh pathway antagonists with
desirable medicinal properties.
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CHAPTER FIVE: PRELIMINARY DATA, FUTURE DIRECTIONS AND
CONCLUSION

Natural products have historically been a rich source for medicines to treat human
disease, and they continue to play a pivotal role in the fields of chemistry, biology, and
medicine [145]. The primary goal of this research was to identify novel alkaloid
inhibitors of the Hh signaling pathway. Our lab has used a Shh-Light II cell assay to
evaluate the biological activity of numerous individual steroidal alkaloids as antagonists
of the Hh signaling pathway (see Figure 5.1). Included in this analysis are the

Figure 5.1
Biological activity of individual steroidal alkaloids for Hh signaling
inhibition. Steroidal alkaloids cyclopamine, veratramine, muldamine, isorubijervine,
tomatidine and solasodine were evaluated in Shh-Light II cells at concentrations a) 5 μM,
b) 1 μM, c) 0.5 μM, and d) 0.1 μM.
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previously mention steroidal alkaloids present in V. californicum – cyclopamine,
veratramine, muldamine and isorubijervine – as well as the structurally similar alklaoids
tomatidine and solasodine, both of which are solanidine-type steroidal alkaloids
speculated to weakly inhibit Smo [89,116]. The variation in pharmacophore features
expressed by Veratrum alkaloids that inhibit the protein Smo could be used to develop a
more thorough understanding of the molecular features that govern alkaloid-based Smo
inhibition. The bioactivity assessment and structural information associated V.
californicum alkaloids combined with structure activity relationship investigation using
the crystal structure of Smo will provide a better understanding of ligand/receptor
interactions leading to the emergence of new therapeutic drugs beyond vismodegib,
sonidegib, and glasdegib. Pharmacophore analysis and free energy binding calculations
using the crystal structure of Smo, coupled with the cell-based assays that have already
been undertaken was initially a principal objective of my dissertation research. I believe
the combination of wet-lab experimentation coupled with computational prediction of
binding affinity is a strategy that will lead to new Smo inhibitors worthy of pursuit by
subsequent students in the McDougal laboratory.
Extraction, separation, and mass spectrum identification of six novel alkaloids
present in V. californicum has been performed. The isolation and biological activity of a
cyclopamine isomer offers a promising project for an ambitious student. This isomer is
present in the root and rhizome of V. californicum, appears at a retention time of 19.4 min
and has been designated as Peak 4 (see star over peak) in Figure 5.2a. Isolation and
characterization of this alkaloid was pursued because the mass of 412.32 was identical to
cyclopamine, and it’s predicted molecular formula of C27H41NO2 was consistent with
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cyclopamine, but the retention time is nearly a minute different than cyclopamine
(Rt=18.7 min). Based on these data, we hypothesized this alkaloid is an isomer of
cyclopamine. MS fragmentation of the target alkaloid (peak 4) is nearly indistinguishable
from cyclopamine (Figure 5.3a and b). However, 2D 1H/13C heteronuclear single
quantum coherence (HSQC) NMR spectra show variation of some proton-carbon
chemical shifts when compared to cyclopamine, as shown in the HSQC overlay of the
two compounds, Figure 5.3c (cyclopamine in blue, and the unknown isomer in green;
overlapping chemical shifts are boxed in red). 2D 1H/13C heteronuclear multiple bond
correlation (HMBC) spectra have also been obtained, and confirm a divergence of
electronic environments for many atoms in each molecule. Bioactivity evaluation of the
cyclopamine isomer has demonstrated no significant difference in the inhibitory activity
between this novel alkaloid and cyclopamine (see Figure 5.3d). Interestingly, differences
in the circular dichroism (CD) spectra indicate that inversion of stereocenters is likely
(see Figure 5.3e).
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Figure 5.2. Alkaloid chromatogram for biomass extracts from the root/rhizome of
V. californicum. Common and unique alkaloids identified by MS are observed, with
veratramine, cyclopamine, isorubijervine and muldamine identified as v, c, i and m,
respectively. The star indicates a cyclopamine isomer which our lab has isolated and used
for bioactivity evaluation, and for which we have begun structure characterization. b)
Chromatogram of the alkaloid standard cocktail replicating the concentrations observed
in root/rhizome extract. c) and d) Comparison of the biological activity of cyclopamine,
crude extracts by plant part, and alkaloid standard cocktails emulating the concentrations
observed in extracts at c) high (cyclopamine, [0.5 µM]) and d) low concentrations
(cyclopamine, [0.1 µM]). No statistically significant difference was observed at higher
alkaloid concentrations in c). However, at lower alkaloid concentrations in d) significant
differences were observed, and * indicates p < 0.05, and ** indicates p < 0.01.
Differences in the inhibitory potential of the crude extract of the stem and the
root/rhizome and their respective alkaloid standard combinations indicate that additional
alkaloids present in the extracts inhibit the Hh signaling pathway.
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Figure 5.3. Comparison of biological and chemical characteristics of cyclopamine
and a potentially novel steroidal alkaloid. MS/MS fragmentation of a) cyclopamine
and b) a cyclopamine isomer. MS/MS fragmentation of the two compounds show very
similar fragment patterns. c) 1H/13C HSQC overlay of cyclopamine (blue) and the
cyclopamine isomer (green). Proton-carbon chemical shifts shared by the two compounds
are boxed in red, and the corresponding protonated carbon atoms are indicated by red
dots on the chemical structure of cyclopamine. d) Biological activity data of cyclopamine
and the isomer in Shh Light II cell assay, showing there is no significant difference
between the inhibitory potential of the two compounds. e) CD spectra of cyclopamine
(blue) and the isomer (red). The discrepancy in the sign of the signal from 220-200 nm
indicates there may be differences in the stereochemistry in absolute configuration of the
two compounds.
Lastly, inclusion of additional model systems beyond the use of Shh-Light II cells
to analyze the effects of Veratrum alkaloids would greatly benefit this project. Although
Shh-Light II cells provide valuable data and are relatively easy cells to work with, the
data obtained from these cells is myopic and only directly relevant to Hh signaling.
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Extension of alkaloid analysis to basal cell carcinoma cells would offer direct cancer
relevance. Analysis of gene expression changes using PCR or proteomic alterations
following alkaloid treatment might yield additional information regarding the
mechanisms underlying the genetic basis of basal cell carcinoma. Further exploration of
promising alkaloid antagonists of Hh pathway inhibition within a zebrafish model will
extend our findings to an organismal model system to address more complex
physiological interactions. Furthermore, this may indicate additional molecular targets for
Veratrum alkaloids beyond Hh signaling that could provide novel avenues for continued
research.
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